Introduction {#s1}
============

Investigations of the gene regulatory networks involved in cell-type specification during embryonic development have been protein-centric for decades. However, given the prevalence of high-throughput sequencing analyses of mammalian genomes, it is now appreciated that non-coding RNAs (ncRNAs) account for at least 50\~80% of transcriptomes ([@bib72]; [@bib79]). Regulatory ncRNAs can be broadly classified based on their size ([@bib57]). Short RNA species (\~20--30 nucleotides \[nt\]), such as microRNAs (miRNAs), have emerged as pivotal modulators of development and disease through mediation of translational repression or mRNA degradation ([@bib27]). Long non-coding RNAs (lncRNAs; \>200 nt) are gaining prominence for their roles in many cellular processes, from chromatin organization to gene expression regulation during embryonic development ([@bib39]; [@bib79]; [@bib81]). Thus, it is not surprising that lncRNAs were recently found to be associated with an array of diseases including cancers, as well as cardiovascular and neurological disorders ([@bib4]).

Accumulating evidence supports that lncRNAs can induce *cis*- and *trans*-acting gene silencing. For example, the lncRNA *Airn* directly represses the paternally-expressed *Igf2r* gene *in cis* for the maintenance of ESC differentiation ([@bib71]) and *Xist* lncRNA triggers *in cis* inactivation of the X chromosome ([@bib44]). The human lncRNA *HOTAIR*, which is expressed from the caudal *HOXC* locus, acts *in trans* to target the *HOXD* cluster for gene silencing ([@bib45]; [@bib78]). Approximately 20% of lncRNAs are associated with polycomb repressive complex 2 (PRC2) ([@bib104]; [@bib37]), which is comprised of many subunits and functions to deposit histone H3K27 trimethylation (H3K27me3) and to suppress gene expression ([@bib25]; [@bib55]; [@bib85]). Although some evidence indicates that lncRNAs might serve as scaffolds for PRC2 assembly and guide PRC2 to specific genomic targets, whether the interaction is specific and necessary in development or disease contexts is still unclear ([@bib13]; [@bib16]; [@bib24]; [@bib23]; [@bib22]; [@bib35]; [@bib36]). Therefore, it is imperative to demonstrate that the specific interactions of lncRNAs with the PRC2 complex are functionally important and have specific regulatory targets to direct development or induce disease in vivo.

We used spinal motor neuron (MN) differentiation as a paradigm to assess these interactions. Although spinal cord development is one of the best characterized processes in the central nervous system (CNS) ([@bib1]; [@bib7]; [@bib9]; [@bib59]; [@bib60]; [@bib66]; [@bib74]), how lncRNAs are involved in its transcription factor-driven gene regulatory networks is unclear ([@bib5]). MN differentiation into subtypes is mediated by the mutually exclusive expression of Hox transcription factors, which is programmed according to the body segment along the rostrocaudal (RC) axis. For example, segmental identity of MNs is defined by the mutually exclusive expression of Hox6, Hox9 and Hox10 ([@bib18]; [@bib41]). In each segment, MNs are grouped into different columns according to their innervating targets. For instance, within the brachial Hox6^on^ segment, MNs are further grouped into axial muscle projecting MNs (Lhx3^on^, MMC) and forelimb-innervating MNs (Foxp1^on^, LMC). Finally, another set of mutually exclusive Hox proteins, such as Hox5 and Hox8 expression in the Foxp1^on^ LMC, further controls the rostral and caudal motor pool identity, which directs motor pools to either innervate proximal or distal muscles in the forelimb ([@bib7]; [@bib19]).

In the spinal cord, polycomb proteins control the exclusion of certain Hox protein expression at specific RC positions and maintain this repression in differentiated cells. Depletion of the polycomb repressive complex 1 (PRC1) component Bmi1 at brachial level causes ectopic expression of Hoxc9 and subjects LMC neurons to a thoracic preganglionic column (PGC) fate. Conversely, elevation of Bmi1 represses Hoxc9 at thoracic level and subjects PGC neurons to an LMC fate ([@bib30]). These observations suggest that specific Hox repression may be maintained in MNs by distinct PRC1 activity levels, programmed along the RC axis. Recently, it was shown that during MN differentiation, *Hox* chromatin is demarcated into discrete domains controlled by opposing RC patterning signals (i.e., retinoic acid (RA), Wnt, and fibroblast growth factors (FGFs)) that trigger rapid and domain-wide clearance of H3K27me3 modifications deposited by PRC2 ([@bib60]). More specifically, RA activates retinoic acid receptors (RARs) and binds to the *Hox1\~5* chromatin domains, which is followed by synchronous domain-wide removal of H3K27me3 to acquire cervical spinal identity. At the tailbud, a gradient of Wnt and FGF signals induces expression of the Cdx2 transcription factor that binds and clears H3K27me3 from the *Hox1\~Hox9* chromatin domains, thereby establishing brachial or thoracic segmental identity ([@bib60]). Together, these findings indicate that epigenetic regulation of *Hox* clusters is critical to initiate and maintain patterns of *Hox* expression and that cross-repressive interactions of combinations of Hox proteins later consolidate the diversification of postmitotic MNs. However, the underlying mechanism that demarcates the histone modifiers at a molecular level is still unclear. Although many lncRNAs are known to regulate these histone modifiers, whether lncRNAs are directly involved in MN fate determination remains to be established.

We found that lncRNAs in the imprinted *Dlk1-Dio3* locus are highly enriched in postmitotic MNs. The *Dlk1-Dio3* locus contains three protein-coding genes (*Dlk1*, *Rtl1*, and *Dio3*) from the paternally inherited allele, and multiple lncRNAs and small ncRNAs are derived from the maternally inherited allele, including *Meg3*, *Rian* (containing 22 box C/D snoRNAs), as well as the largest miRNA mega-cluster in mammals (*anti-Rtl1*, which contains the *miR-127*/*miR-136* cluster of 7 miRNAs, and *Mirg* that within the *miR-379*/*miR-410* cluster). Interestingly, all of the ncRNAs are regulated by a common *cis*-element and epigenetic control, resulting in a presumable large polycistronic transcription unit ([@bib17]; [@bib50]; [@bib82]). Although the *Dlk1-Dio3* locus is well known to play crucial roles in stem cells ([@bib51]; [@bib50]; [@bib75]), we unexpectedly found that expressions of *Meg3* and other lncRNAs from the *Dlk1-Dio3* locus are also all enriched in postmitotic MNs. However, whether this locus functions during neural development had not been explored previously. Here, we show that lncRNAs in the imprinted *Dlk1-Dio3* locus shape postmitotic MNs by inhibiting progenitor and non-neural genes, and they also control MN subtype identity by regulating Hox expression. Our results provide strong evidence for the critical function of lncRNAs during MN development, emphasizing their physiological functions during embryonic development.

Results {#s2}
=======

Identification of cell-type-specific lncRNAs during MN differentiation {#s2-1}
----------------------------------------------------------------------

As epigenetic landscape remodelling and the cell fate transition during MN differentiation are well characterized ([@bib9]; [@bib48]; [@bib93]), we took advantage of an ESC differentiation approach that can recapitulate MN development to systematically identify cell lncRNAs during this differentiation process. Firstly, an ESC line harbouring the MN transgenic reporter *Hb9::GFP* was harnessed into MNs ([@bib96]), and we then sequentially collected RA-induced nascent neural epithelia (Hoxa1^on^, NE at day 2), MN progenitors (Olig2^on^, pMN at day 4), and postmitotic MNs (Hb9::GFP^on^, postmitotic MNs at day 7) by fluorescence-activated cell sorting (FACS). Simultaneously, spinal interneurons (INs) derived from \[smoothened agonist; SAG\]^low^ conditions were collected and Hb9::GFP^off^ cells were sorted at day 7 as controls ([Figure 1A](#fig1){ref-type="fig"}). Next, we performed strand-specific RNA-seq across libraries preserving non-polyadenylated transcripts while removing ribosomal RNAs, since many lncRNAs are non-polyadenylated ([@bib100]; [@bib103]), and carried out de novo transcriptome assembly ([@bib75]) to discover novel lncRNAs that might be specifically enriched during MN development (detailed in the Materials and methods and summarized in [Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}; [Supplementary file 1](#supp1){ref-type="supplementary-material"}). Several known markers for each cell type during MN differentiation were accurately recovered, corroborating the high quality and specificity of our RNA-seq data ([Figure 1B](#fig1){ref-type="fig"}). Our approach yielded 10,177 lncRNAs, 752 of which (7.39%) were previously unidentified from the Ensemble mm10 database. We also found that 4295 (77.78%) of our identified lncRNAs overlapped with recently reported spinal MN-related lncRNAs, which were discovered by poly A^+^-enriched RNA-seq approaches ([@bib2]; [@bib66]) ([Figure 1---figure supplement 1B](#fig1s1){ref-type="fig"}). Finally, we removed minimally expressed transcripts (TMM normalized read count \<10 in all samples), which left 602 expressed lncRNAs ([Supplementary file 2](#supp2){ref-type="supplementary-material"}). Based on stage-specific scores (see Materials and methods), 70 stage-signature lncRNAs during the ESC\~MNs differentiation process were uncovered (ESC, NE, pMN, MN, and IN in [Figure 1C](#fig1){ref-type="fig"}). Compared to protein-coding genes, both annotated lncRNAs and novel lncRNAs (newly identified in our de novo transcriptome assembly) had higher cell-type specificity ([Figure 1D](#fig1){ref-type="fig"}, Kolmogorov-Smirnov test, p=1.41 × 10^−9^ and p=3.53 × 10^−7^, respectively; see Materials and methods), implying that lncRNAs might play specific roles in each cell type during ESC\~MN differentiation.

![Identification of cell-type-specific lncRNAs during motor neuron differentiation.\
(**A**) Schematic illustration of the differentiation process from *Hb9::GFP* ESCs to spinal MNs. RA: retinoic acid. SAG: Smoothened agonist. ESC: embryonic stem cell. NE: neural epithelium. pMN: motor neuron progenitor. MN: motor neuron. IN: interneuron. (**B and C**) Heatmaps presenting the abundances of known cell transcription factors (**B**) and the abundances of lncRNA signatures (**C**) across each stage from ESCs to postmitotic MNs and INs (color indicates specificity scores). (**D**) Cumulative distributions (above) and probability distributions (below) of the stage specificity score of different categories of genes (protein coding genes \[red\], annotated lncRNAs \[blue\] and novel lncRNAs \[black\]), representing a measure of differential expression for each transcript across the cell types. The distribution reveals that annotated lncRNAs and novel lncRNAs manifest significantly higher specificity (according to Kolmogorov-Smirnov tests) than protein-coding genes.](elife-38080-fig1){#fig1}

The *Dlk1-Dio3* locus-derived lncRNAs are enriched in the nuclei of postmitotic MNs {#s2-2}
-----------------------------------------------------------------------------------

To identify developmentally up-regulated lncRNAs, we compared day 4 pMNs vs. day 7 postmitotic MNs ([Figure 2A](#fig2){ref-type="fig"}). Furthermore, to retrieve cell-type-specific lncRNAs, we performed a pairwise comparison of day 7 postmitotic MNs against day 7 INs ([Figure 2B](#fig2){ref-type="fig"}). We identified 117 lncRNA candidates from our analysis as being postmitotic MN-enriched. We further selected several MN-lncRNAs that manifested high normalized reads from RNA-seq data and verified their MN-specific expression by qPCR ([Figure 1---figure supplement 1C](#fig1s1){ref-type="fig"}). Interestingly, the lncRNAs *Meg3*, *Rian*, and *Mirg*, which are transcribed from the imprinted *Dlk1-Dio3* locus on mouse chromosome 12qF, all manifested strong enrichment in postmitotic MNs (simplified schematic locus depicted in [Figure 2C](#fig2){ref-type="fig"}, detailed locus information in [Figure 2---figure supplement 1A](#fig2s1){ref-type="fig"}). Since these lncRNAs are conserved amongst placental mammals ([@bib69]), we chose to characterize their functions in greater detail.

![*Dlk1-Dio3* locus-derived lncRNAs are enriched in postmitotic motor neurons.\
(**A and B**) MA plots demonstrate that *Meg3*, *Rian*, and *Mirg* are postmitotic (day 7 MNs ~vs.~ day 4 pMNs; **A**) MN signature (day 7 MNs ~vs.~ day 7 INs; **B**) lncRNAs. *X*-axis: mean abundance; *Y*-axis: log~2~ fold-change. (**C**) Illustration of the imprinted *Dlk1-Dio3* locus. The lncRNAs of the maternally-inherited allele (in red) are on mouse chromosome 12. The miRNA and C/D snoRNA genes are shown by hairpin loops and triangles, respectively. (**D**) Comparison of ChIP-seq for MN transcription factors (Lhx3 and Isl1), H3K4me3, and H3K27ac, together with ATAC-seq of the *Dlk1-Dio3* locus. (**E**) In situ hybridization shows that *Meg3* is gradually enriched and restricted in postmitotic MNs in the developing spinal cord. (**F**) In situ hybridization together with adjacent sections of immunostaining on E12.5 segmental spinal cords demonstrate that *Meg3* is enriched at brachial and thoracic MNs (Isl1/2^on^), but no preference for columnar MN subtypes was revealed for Foxp1 or Lhx3. (**G and H**) RAR binding and recruitment of the elongating form of Pol2 to the *Meg3* transcription start site (TSS) occur within 8 hr of retinoic acid (RA) exposure.](elife-38080-fig2){#fig2}

To investigate why *Meg3-Rian-Mirg* are highly enriched in postmitotic MNs, we examined the binding landscape of MN-specific transcription factors (i.e., Lhx3 and Isl1), histone modifications (H3K4me3 and H3K27ac), and chromatin accessibility (ATAC-seq) across the *Meg3-Rian-Mirg* locus from previously published studies ([Figure 2D](#fig2){ref-type="fig"}) ([@bib59]; [@bib66]; [@bib77]). Within this locus, we uncovered an MN-specific active chromatin region that possesses enhancer/promoter characteristics with direct MN-specific transcription factor binding ([Figure 2D](#fig2){ref-type="fig"}). Furthermore, overexpression of MN-TFs in a maternally-inherited intergenic differentially methylated region deletion (*IG-DMR^matΔ^*) ESC line, which leads to simultaneous silencing of all maternally-expressed lncRNAs in the *Meg3-Rian-Mirg* locus but leaves the MN-TF binding site intact ([Figure 2---figure supplement 1A](#fig2s1){ref-type="fig"}) ([@bib51]; [@bib50]), can robustly induce *Meg3* expression ([Figure 2---figure supplement 1B](#fig2s1){ref-type="fig"}). Therefore, we suggest that MN-TFs bind and directly activate *Meg3* during ESC\~MN differentiation.

We further performed *Meg3* in situ hybridization and immunostaining of the adjacent sections along the RC axis from E10.5\~12.5. We found that *Meg3* expression: (1) is enriched in the mantle zone of the developing spinal cord during development and is gradually enriched in postmitotic MNs (Isl1/2^on^ cells) after E12.5; (2) has no preference for columnar MN subtypes, as revealed by Foxp1 (LMC-MNs) and Lhx3 (MMC-MNs) immunostaining; and (3) exhibits rostral high (brachial and thoracic) and caudal low (lumbar) asymmetry after E12.5 ([Figure 2E and F](#fig2){ref-type="fig"}).

Why does *Meg3* exhibit strong enrichment in the brachial spinal cord? Given that previous reports indicate that rostral *Hox* genes enriched in the brachial spinal cord are mediated by an RA gradient ([@bib60]; [@bib68]), we hypothesized that *Meg3* might also be induced by RA. To examine this possibility, we checked if there is any RA-driven binding to RAR sites near the *Meg3* promoter ([Figure 2G](#fig2){ref-type="fig"}) ([@bib53]). Interestingly, we found that RA treatment results in novel binding of RAR directly to the *Meg3* promoter, as well as subsequent recruitment of the basal transcription complex (Pol2-S5P in [Figure 2H](#fig2){ref-type="fig"}). Moreover, we observed that *Meg3* is induced after the addition of RA in *IG-DMR^matΔ^* ESCs after 8 hr ([Figure 2---figure supplement 1C](#fig2s1){ref-type="fig"}), indicating that RA/RAR activation triggers the strong *Meg3* expression in rostral brachial MNs.

Finally, to characterize the abundance and subcellular localization patterns of *Meg3* at a cellular level, we designed a set of single molecule RNA FISH probes specific to *Meg3* and examined their expression in ESC\~MNs. We observed a speckled pattern of *Meg3* expression enriched in the nucleus, suggesting it has a potential function in gene regulation ([Figure 2---figure supplement 1D](#fig2s1){ref-type="fig"}). Furthermore, qPCR of subcellular-fractionated RNAs from ESC\~MNs validated that *Meg3* is not only enriched in the nucleus, but that it is also chromatin-associated ([Figure 2---figure supplement 1E](#fig2s1){ref-type="fig"}; *Gapdh* as cytoplasmic marker, *Rnu1* (*U1* snRNA) as nuclear marker, and *Kcnq1ot1* as a chromatin-associated RNA control). Together, these findings suggest that lncRNAs in the *Dlk1-Dio3* locus are postmitotic MN-enriched, and that they are directly activated by MN-TFs and RA/RAR. At a cellular level, *Meg3* is highly enriched in MN nuclei and is chromatin-associated, indicating a potential function in chromatin regulation.

*Meg3* facilitates interaction of the PRC2 complex with Jarid2 in ESC\~MNs {#s2-3}
--------------------------------------------------------------------------

While several previous reports have revealed that interactions between Jarid2 and ncRNAs regulate PRC2 recruitment to chromatin, including lncRNAs in the *Dlk1-Dio3* locus of ESCs ([@bib16]; [@bib35]; [@bib36]), the roles of PRC2/Jarid2 in postmitotic cells are less clear. Unlike the PRC2 complex, Jarid2 is known to have diverse cell-type-specific functions ([@bib42]). Surprisingly, we found that expression of *Jarid2* was reactivated in postmitotic MNs, pointing to a possible specific regulation in this cell type ([Figure 3---figure supplement 1A](#fig3s1){ref-type="fig"} upper panel) ([@bib89]). Moreover, compared to several known lncRNAs that interact with PRC2 complex, *Meg3* and *Rian* manifested much more abundant expressions in the postmitotic MNs ([Figure 3---figure supplement 1A](#fig3s1){ref-type="fig"} lower panel). This prompted us to examine if lncRNAs in the *Dlk1-Dio3* locus bind to the PRC2 complex and maintain postmitotic MN fate by controlling the H3K27me3 landscape. To test this hypothesis, we first demonstrated that immunoprecipitation (IP) of endogenous PRC2 complex components (i.e., Ezh2 and Suz12), as well as the PRC2 cofactor Jarid2, from ESC\~MNs specifically retrieves *Meg3*, *Rian* and *Mirg* RNA, whereas the nuclear ncRNA *Rnu1* and the lncRNA *Malat1* were not captured by Ezh2, Jarid2, or Suz12 ([Figure 3A](#fig3){ref-type="fig"}). Given that *Rian* and *Mirg* are further processed to snoRNAs and miRNAs ([@bib50]) and that *Meg3* is known to regulate pluripotency ([@bib86]), imprinting ([@bib17]), and PRC2 function ([@bib104]), we focused on biochemical characterization of *Meg3*. Several *Meg3* isoforms have previously been documented, so we scrutinized across the entire *Meg3* locus (\~31 kb) and found that two isoforms, *Meg3^v1^* and *Meg3^v5^* (Ensemble mm10 database), are predominantly expressed in Hb9::GFP^on^ MNs ([Figure 3---figure supplement 1B,C](#fig3s1){ref-type="fig"}). Moreover, *Meg3^v1^* and *Meg3^v5^* isoforms account for more than 99% of *Meg3* transcripts than other isoforms during ESC\~MN differentiation. ([Figure 3---figure supplement 1D](#fig3s1){ref-type="fig"}) ([@bib36]; [@bib105]). Interestingly, *Meg3^v1^* and *Meg3^v5^* have mutually exclusive exon sequences ([Figure 3---figure supplement 1E](#fig3s1){ref-type="fig"}), raising the possibility that the two isoforms might exert different functions. However, both purified biotinylated *Meg3^v1^* and *Meg3^v5^* RNA retrieved Ezh2 from cell nuclear extracts of ESC\~MNs ([Figure 3B](#fig3){ref-type="fig"}; *GFP* RNA was used as a negative control). These results suggest that these *Meg3* isoforms directly interact with PRC2/Jarid2 complexes and might facilitate association of the PRC2 complex with Jarid2.

![*Meg3* facilitates the non-stoichiometric interaction of the PRC2 complex and Jarid2.\
(**A**) Ezh2, Jarid2, and Suz12 immunoprecipitation specifically retrieves *Meg3* RNA isoforms (**v1 and v5**). *Rnu1* RNA and *Malat1* lncRNA are negative controls. 10% input was used to normalize the retrieval efficiency (error bars represent SD, n = 3 independent experiments). Immunoblotting reflects the recovery of Ezh2, Jarid2 and Suz12 proteins using the corresponding antibodies. (**B**) In vitro-transcribed, biotinylated *Meg3* RNA isoforms retrieved Ezh2. (**C**) Ezh2 interacts with Jarid2 in ESC\~MNs, but knockdown of *Meg3* impairs this interaction. The abundance of Jarid2 is shown on the right (N.S.: not significant; error bars represent SD, n = 3 independent experiments; \*\* p-value\<0.01 by Student's *t*-test). (**D and E**) The design of inducible 'Tet-On' ESC lines expressing *Meg3^v1^* or *Meg3^5^* under the doxycycline (Dox)-regulated promoter. In the presence of Dox, the reverse tetracycline-controlled transactivator (rtTA) is recruited to the TRE (tetracycline response element), thereby initiating robust transcription of *Meg3^v1^* or *Meg3^v5^,* respectively. (**F**) Overexpression of *Meg3^v1^* or *Meg3^v5^* does not alter the protein levels of Ezh2 or Jarid2. (**G**) *Meg3^v5^* but not *Meg3^v1^* stimulates more Ezh2 and Jarid2 interaction. The abundances of Jarid2 are shown on the right (FC: fold-change; N.S.: not significant; error bars represent SD, n = 3 independent experiments; \* p-value\<0.05, \*\* p-value\<0.01 by Student's *t*-test).](elife-38080-fig3){#fig3}

As the PRC2 complex and Jarid2 are known to interact in a non-stoichiometric manner ([@bib70]; [@bib73]), we further examined if *Meg3* facilitates the interaction between PRC2 complex and Jarid2. To test this possibility, we performed IP with Ezh2 (a core component of PRC2) to retrieve Jarid2 from ESC\~MNs ([Figure 3C](#fig3){ref-type="fig"}). We first verified that *Meg3* knockdown (KD) did not affect the protein abundance of Ezh2/Jarid2, but we did observe that it undermined the interaction between Ezh2 and Jarid2, suggesting that *Meg3* facilitates this interaction ([Figure 3C](#fig3){ref-type="fig"} and [Figure 3---figure supplement 1F](#fig3s1){ref-type="fig"}). We then investigated if the two *Meg3* isoforms have differing abilities to facilitate Ezh2/Jarid2 binding by generating two locus-defined Tet-ON-inducible *Meg3* ESCs ([Figure 3D](#fig3){ref-type="fig"}, *iMeg3^v1^* and *iMeg3^v5^*). Upon doxycycline induction, both *Meg3* isoforms were induced \~20--50 fold, yet the abundance of Ezh2/Jarid2 remained unaffected ([Figure 3E and F](#fig3){ref-type="fig"}). *Meg3^v5^* overexpression in ESC\~MNs significantly increased the binding of Ezh2 and Jarid2, whereas *Meg3^v1^* overexpression [Figure 3E](#fig3){ref-type="fig"}; [Figure 3F](#fig3){ref-type="fig"} had a minimal effect ([Figure 3G](#fig3){ref-type="fig"}), indicating that *Meg3^v5^* is a strong facilitator of the binding of the PRC2 complex and Jarid2. Accordingly, we suggest that *Meg3*, and particularly the *Meg3^v5^* isoform, facilitates the binding of the PRC2 complex and Jarid2 in postmitotic MNs.

*Dlk1-Dio3* locus-derived lncRNAs maintain the epigenetic landscape in postmitotic MNs {#s2-4}
--------------------------------------------------------------------------------------

To test if the binding of Ezh2/Jarid2 by the lncRNAs in the *Dlk1-Dio3* locus is important to maintain the epigenetic landscape in postmitotic MNs, we systematically analyzed genome-wide H3K27me3 profiles of control and *IG-DMR^matΔ^* ESC\~MNs by ChIP-seq (chromatin immunoprecipitation-sequencing) ([Figure 4A](#fig4){ref-type="fig"}). To overcome the complication of concomitant up-regulation of paternal coding genes in *IG-DMR^matΔ^* ESCs ([@bib51]; [@bib50]), we further established two retrovirus-based short hairpin RNAs (shRNAs) targeting *Meg3* and used a knockdown approach to prevent impairment of DMR sites. Both shRNAs reduced the expression of *Meg3* by an average of \~90% compared to endogenous levels in ESC\~MNs ([Figure 4---figure supplement 1A](#fig4s1){ref-type="fig"}). As negative controls, we performed independent infections with retroviruses containing scrambled shRNA with no obvious cellular target RNA. We selected two stable *Meg3* KD ESCs (referred to as H6 and K4 hereafter) that had the best ESC morphology for further experiments. Verification by qPCR indicated that the expressions of two other lncRNAs, *Rian* and *Mirg*, from the maternal allele of the *Dlk1-Dio3* imprinted locus were all significantly down-regulated in *Meg3* KD MNs, whereas paternal genes were unaffected ([Figure 4---figure supplement 1A](#fig4s1){ref-type="fig"}). This finding is consistent with a previous report indicating that *Meg3-Rian-Mirg* probably represents a single continuous transcriptional unit ([@bib17]).

![Loss of *Dlk1-Dio3* locus-derived lncRNAs in MNs leads to dysregulation of neural progenitor and caudal *Hox* genes.\
(**A**) Genome-wide profiling of H3K27me3 by ChIP-seq and gene expression by Agilent microarray in control, *IG-DMR^matΔ^*, and *Meg3* KD ESC\~MNs. Venn diagram shows the number of genes that are up-regulated in both *IG-DMR^matΔ^* and *Meg3* KD MNs while also displaying the reduction of H3K27me3 epigenetic landscape. Loss of *Meg3* imprinted lncRNAs is related to the up-regulation of progenitor genes, as well as *Hox* genes. (**B and C**) Heatmaps illustrating the expression profiles of ESC\~MNs in control scrambled and *Meg3* KD lines. The color indicates the log~2~ fold-change in signal intensity between ESCs and ESC\~MNs. Genes in light grey are not represented in the microarrays. Loss of *Meg3* imprinted lncRNAs results in ectopic expression of progenitor genes in (**B**), and a majority of caudal *Hox* genes (*Hox8\~13*) in (**C**), with concomitant down-regulation of H3K27me3 levels.](elife-38080-fig4){#fig4}

We then performed H3K27me3 ChIP-seq of control and *Meg3* KD MNs. We observed a trend of global down-regulation of H3K27me3 in both independent experiments of *Meg3* KD MNs, most likely a reflection of compromised Ezh2/Jarid2 interaction ([Figure 4---figure supplement 1B](#fig4s1){ref-type="fig"}). Since the response to PRC2 activity change in a given cell type might be context-dependent ([@bib22]), we sought to identify relevant genes in MNs regulated by *Dlk1-Dio3* locus-derived lncRNAs based on the loss of H3K27me3. To achieve this, we profiled gene transcriptomes of control, *IG-DMR^matΔ^*, and *Meg3* KD ESC\~MNs. Next, we compared the co-upregulated genes between *IG-DMR^matΔ^* and *Meg3* KD ESC\~MNs, together with H3K27me3 landscape upon the loss of ncRNAs in the *Dlk1-Dio3* locus ([Figure 4A](#fig4){ref-type="fig"} and [Figure 4---figure supplement 1C](#fig4s1){ref-type="fig"}). This approach revealed 585 genes in MNs that displayed down-regulation of the H3K27me3 epigenetic landscape and concomitant up-regulation of gene expression upon loss of the *Meg3* lncRNAs ([Figure 4A](#fig4){ref-type="fig"}). Gene ontology (GO) analysis of these genes revealed significant enrichment for RC patterning and progenitor genes, and strikingly so for homeodomain *Hox* genes ([Figure 4---figure supplement 1D](#fig4s1){ref-type="fig"}; false discovery rate (FDR) q-value ≤0.05).

Subsequently, we observed that MN progenitor (*Pax6* and *Irx3*) and majority of caudal *Hox* genes (*Hox8\~13*) were up-regulated with a concomitant down-regulation of the H3K27me3 epigenetic landscape ([Figure 4B and C](#fig4){ref-type="fig"}). We corroborated this finding by generating a third *Meg3* KD ESC line (I6) and confirming that all *Meg3* KD ESC\~MNs exhibited imbalanced expression of 3\' and 5\' *Hox* genes across entire *Hox* clusters ([Figure 4---figure supplement 1E](#fig4s1){ref-type="fig"}). Thus, for both *Meg3* KD and *IG-DMR^matΔ^* ESC\~MNs, dysregulation of progenitor and caudal *Hox* gene expression is apparent, likely due to loss of the robustness of the epigenetic landscape of postmitotic MNs.

If *Meg3* scaffolds PRC2/Jaird2 to maintain the silenced H3K27me3 epigenetic landscape in progenitor and caudal *Hox* genes of postmitotic MNs, we predicted that (1) the binding patterns of Ezh2/H3K27me3 would display concordant tendency in MNs; and (2) the bindings of Ezh2/Jarid2 to the gene loci of progenitor and caudal *Hox* genes in MNs would be compromised upon the loss of *Meg3*. Consistent with our prediction, we verified that (1) the epigenetic landscapes of H3K27me3 in the progenitor and caudal *Hox* genes uncovered here are concordant with Ezh2 enrichment revealed by a previous study that used the same ESC\~MN differentiation approach to generate cervical Hoxa5^on^ MNs ([Figure 4---figure supplement 2A,B](#fig4s2){ref-type="fig"}) ([@bib66]); (2) Upon *Meg3* KD, the bindings of Ezh2/Jaird2 to progenitor (i.e., *Pax6* and *Irx3*) and caudal *Hox* (i.e., *Hoxc8*) genes were concomitantly reduced ([Figure 4---figure supplement 2C--E](#fig4s2){ref-type="fig"}). Taken all together, these results suggest that *Meg3* bridges the PRC2/Jarid2 complex to perpetuate the rostral MN cell fate by silencing epigenetic state of MN progenitor and caudal *Hox* genes.

*IG-DMR^matΔ^* embryos manifest dysregulation of progenitor genes in postmitotic MNs {#s2-5}
------------------------------------------------------------------------------------

To corroborate the observed phenotype of *IG-DMR^matΔ^* ESC\~MNs, we further scrutinized the MN phenotype in *IG-DMR^matΔ^* embryos. Consistent with previous studies, *IG-DMR^matΔ^* embryos died soon after E16 ([@bib51]), so we analyzed MN phenotypes from E10.5\~E14.5 in this study. We first verified that the expression of *Meg3* is still lacking in the developing spinal cord of E14.5 *IG-DMR^matΔ^* embryos ([Figure 5---figure supplement 1A](#fig5s1){ref-type="fig"}). Ventral neuronal progenitor patterning was not affected in the *IG-DMR^matΔ^* embryos revealed by Olig2 and Nkx2.2 ([Figure 5---figure supplement 1B,C](#fig5s1){ref-type="fig"}). We then checked the dorsal progenitor proteins Pax6 and Irx3. Compared to the control littermates, we observed a significant increase in the percentage of Pax6^on^ (45% penetrance, n = 5/11), and Irx3^on^ cells (100% penetrance, n = 8/8) for postmitotic MNs (Is11/2^on^) along the entire RC axis of the ventral spinal cord in the *IG-DMR^matΔ^* embryos ([Figure 5A and C](#fig5){ref-type="fig"}, only the cervical segment is shown; quantifications shown in [Figure 5B and D](#fig5){ref-type="fig"}). However, Hb9^on^ and Isl1(2)^on^ MNs were comparable between the control and *IG-DMR^matΔ^* embryos at E10.5 ([Figure 5E and F](#fig5){ref-type="fig"}). Although dorsal progenitor genes were aberrantly up-regulated in the postmitotic MNs, production of MNs remained relatively unaffected, suggesting that the generation of MNs is still intact with the co-expressed progenitor/postmitotic genes in the *IG-DMR^matΔ^* embryos ([Figure 5G](#fig5){ref-type="fig"}). This outcome is consistent with the postmitotic expression of *Meg3* and its function to maintain the silenced epigenetic state of progenitor genes.

![*IG-DMR^matΔ^* mice ectopically turn on progenitor genes in postmitotic MNs.\
(A \~ D) *IG-DMR^matΔ^* embryos display ectopic Pax6^on^ and Irx3^on^ cells in the postmitotic Is11(2)^on^ MNs (partial penetrance for Pax6, n = 5/11 at E11.5; whereas Irx3 displays 100% penetrance, n = 8/8. Error bars represent SD, \*\* p-value\<0.01 by Student's *t*-test). (**E**) Generation of generic MNs (Hb9^on^, Lhx3^on^, and Isl1/2^on^) is not affected in spinal cords of *IG-DMR^matΔ^* mice at E10.5. (**F**) Quantification of postmitotic MNs (number of positive cells per 15 μm brachial ventral-half sections) in wild type control and *IG-DMR^matΔ^* embryos (error bars represent SD, n = 3 embryos at E10.5; N.S.: not significant by Student's *t*-test). (**G**) Summary of ectopic progenitor gene expression in postmitotic MNs of the *IG-DMR^matΔ^* embryos.](elife-38080-fig5){#fig5}

*IG-DMR^matΔ^* embryos display caudalized *Hox* genes in cervical MNs {#s2-6}
---------------------------------------------------------------------

Next, we checked if the expression of Hox proteins is affected in *IG-DMR^matΔ^* embryos. We first assessed how loss of *Dlk1-Dio3* locus-derived lncRNAs affected the specification of segmental MNs, marked by brachial (Hoxc6), thoracic (Hoxc9), and lumbar (Hoxd10) Hox levels. We observed comparable numbers of cells expressing respective Hox proteins at each segmental level between control and mutant embryos ([Figure 5---figure supplement 1D,E](#fig5s1){ref-type="fig"}). Columnar identities of axial (Lhx3^on^) and limb-innervating MNs (Foxp1^on^) were also largely unaffected in the *IG-DMR^matΔ^* embryos ([Figure 5---figure supplement 1F,G](#fig5s1){ref-type="fig"}).

To further examine MN subtype diversification within the limb-innervating MNs, we checked the Hox proteins involved in pool specification ([@bib7]; [@bib19]). Whereas reciprocal expression of Hoxa5 and Hoxc8 was maintained along the RC axis in the Hox6^on^ LMC MNs of control embryos, Hoxc8 was expanded rostrally into Hoxa5^on^ territory in *IG-DMR^matΔ^* embryos, along with a significant increase of the Hoxc8-mediated downstream motor pool genes, Pea3 and Scip (n *=* 5 embryos in [Figure 6A and C](#fig6){ref-type="fig"} for rostral brachial segments and [Figure 6B and D](#fig6){ref-type="fig"} for caudal brachial segments; quantification in [Figure 6E and F](#fig6){ref-type="fig"}). The reduction of Hoxa5 was not attributable to apoptosis, as cCasp3^on^ cells were comparable in both control and *IG-DMR^matΔ^* mutant embryos (data not shown). Taken together, the switching of Hoxa5^on^ to Hoxc8^on^ in MNs of *IG-DMR^matΔ^* embryos is not transient, which leads to a concomitant change in motor pool fate ([Figure 6G](#fig6){ref-type="fig"}).

![*IG-DMR^matΔ^* mice manifest switched MN subtype identity.\
(A \~ D) Ectopic expansion of Hoxc8 and downstream Pea3^on^ and Scip^on^ MN pools in the rostral brachial segment, with a concomitant decrease of Hoxa5^on^ MNs for E11.5\~E12.5 *IG-DMR^matΔ^* embryonic spinal cord sections. Expression of Hoxc8 in the caudal brachial region remains unaffected (**B and D**). (**E and F**) Quantification of the numbers and distributions of Hoxa5^on^, Hoxc8^on^, Pea3^on^, and Scip^on^ MNs in the control and *IG-DMR^matΔ^* mice from serial sections along the rostrocaudal axis (N.S.: not significant; error bars represent SD, n = 5; \* p-value\<0.05, \*\* p-value\<0.01 by Student's *t*-test). (**G**) Summary of the motor neuron phenotype in the *IG-DMR^matΔ^* embryos.](elife-38080-fig6){#fig6}

Peripheral innervation defects in *IG-DMR^matΔ^* mutants {#s2-7}
--------------------------------------------------------

To further examine the impact of switching the MN pool subtype identity of LMC-MNs, we assessed the potential trajectory and target selectivity of motor axons in wild type control and *IG-DMR^matΔ^* embryos ([@bib49]). We bred *IG-DMR^matΔ^* mutants to a transgenic line of *Hb9::GFP* mice in which all motor axons are labeled with GFP and then analyzed the overall pattern of limb innervation. First, the images of motor nerves from light sheet microscopy were converted into panoramic 3D images (upper panel in [Figure 7A](#fig7){ref-type="fig"}; [Videos 1](#video1){ref-type="video"} and [2](#video2){ref-type="video"}). The overall trajectory of each motor nerve was reconstructed by Imaris (lower panel in [Figure 7A](#fig7){ref-type="fig"}) and this conversion enabled semi-automatic calculation of the number of motor nerve terminals in each skeletal muscle, as well as comparison of the extent of motor axon arborization between skeletal muscles (see Materials and methods for details). Under higher magnification with better resolution, we observed the terminal arbors of suprascapular (Ss) nerves of scapulohumeralis posterior muscles and axillary (Ax) nerves were significantly eroded and reduced ([Figure 7B and C](#fig7){ref-type="fig"}), consistent with the caudalized switch from Hoxa5 to Hoxc8 expression within LMC neurons. Concomitantly, increased arborization complexity of distal muscle-innervating nerves, including posterior brachial cutaneous (PBC) nerves were manifested in the *IG-DMR^matΔ^* embryos ([Figure 7D](#fig7){ref-type="fig"}, quantification in 7E, n = 6, p\<0.01, Mann--Whitney U test). Thus, the *IG-DMR^matΔ^* mutants displayed deficiencies in peripheral innervation of MNs, which might be a consequence of dysregulation of Hox proteins and/or other axon arborization genes in the absence of lncRNAs from the *Dlk1-Dio3* locus.

![Motor axon innervation defects in the *IG-DMR^matΔ^* embryos.\
(**A**) Panoramic views from different angles of control and *IG-DMR^matΔ^; Hb9::GFP* embryos at E13.5 using light sheet microscopy (Upper panel). Details of each viewing angle are illustrated in [Videos 1](#video1){ref-type="video"} and [2](#video2){ref-type="video"}. Reconstruction of motor nerve positions by Imaris (see Materials and methods for details) is illustrated in the lower panel. Suprascapular nerve (Ss, yellow); axillary nerve (Ax, purple); musculocutaneous nerve (Mus, green); radial nerve (Rad, blue); posterior brachial cutaneous nerve (PBC, pink). (B \~ D) Higher magnification of MN innervations in the forelimbs of E13.5 control and *IG-DMR^matΔ^; Hb9::GFP* mice. Mutant mice display defects in Ss and Ax axonal branching, concomitant with more PBC axonal branching. Semi-automatic highlighting of the axonal branching and nerve trajectories is used and quantified by Imaris. (**E**) Quantification of the axonal branching and nerve trajectories for E13.5 control and *IG-DMR^matΔ^; Hb9::GFP* mice by Imaris (see Materials and ﻿ethods for details) (n = 6, p\<0.01, Mann--Whitney U test).](elife-38080-fig7){#fig7}

###### Panoramic views from different angles of forelimb in control *Hb9::GFP* embryos at E13.5 using light sheet microscopy.

###### Panoramic views from different angles of forelimb in *IG-DMR^matΔ^* ; *Hb9::GFP* embryos at E13.5 using light sheet microscopy.

*Meg3* functions as a potent lncRNA in the *Meg3-Rian-Mirg* locus to regulate MN cell fate {#s2-8}
------------------------------------------------------------------------------------------

As our current and previous results indicated that the expressions of most lncRNAs in the *Meg3-Rian-Mirg* locus are reduced upon *Meg3* KD and in *IG-DMR^MatΔ^* ([Figure 4---figure supplement 1A](#fig4s1){ref-type="fig"})([@bib50]), it remains puzzling if these ncRNAs work independently or synergistically in this locus to regulate MNs. To further parse this question, we generated two single lncRNA *Rian^Δ/Δ^* and *Mirg^Δ/Δ^* ESCs respectively by using CRISPR-Cas9 mediated approaches ([Figure 8A](#fig8){ref-type="fig"}). The design of the targeted deletion regions of *Meg3* and *Rian* followed two previous studies ([@bib31]; [@bib40]), which led to a 23 kb deletion in the *Rian^Δ/Δ^* ESC and a 20 kb deletion in the *Mirg^Δ/Δ^* ESC ([Figure 8A](#fig8){ref-type="fig"}). We first verified that the paternal gene (i.e., *Dlk1*) is not affected in either *Rian^Δ/Δ^* or *Mirg^Δ/Δ^* ESCs. In the *Rian^Δ/Δ^* ESC, expressions of *Meg3* and *Mirg* were relatively unaffected, whereas that of *Rian* was compromised. Conversely, only expression of *Mirg* was impaired significantly in the *Mirg^Δ/Δ^* ESCs, but expressions of *Meg3* and *Rian* manifested minimal changes in that cell line ([Figure 8B](#fig8){ref-type="fig"}). Upon differentiation, *Meg3* KD ESC\~MNs showed ectopic up-regulated expressions of progenitor and caudal *Hox* genes ([Figure 4](#fig4){ref-type="fig"} and [Figure 8C](#fig8){ref-type="fig"}). In contrast, expression of *Hoxa5* remained unchanged in the *Rian^Δ/Δ^* and *Mirg^Δ/Δ^* ESC\~MNs, and *Pax6* and *Hoxc8* expressions were also unaltered, with similar expression levels to controls ([Figure 8C](#fig8){ref-type="fig"}). These results indicate that *Meg3* might be the major regulatory lncRNA responsible for the observed MN phenotype displayed by the *IG-DMR^matΔ^* embryos ([Figure 8D](#fig8){ref-type="fig"}).

![Dissection of individual roles of lncRNAs in the *Meg3-Rian-Mirg* locus in ESC\~MNs.\
(**A**) Illustration of the sgRNAs target sites and sequences for the sgRNA:Cas9-mediated *Rian* and *Mirg* deletions respectively. Deleted sequences shown in *Rian^Δ/Δ^* and *Mirg^Δ/Δ^* ESC lines. The PAM sites are displayed in green; the sgRNA target sequences are reflected in red. (**B**) Heatmaps representing the abundances of the paternal gene (*Dlk1*) and maternal lncRNAs (*Meg3*, *Rian*, and *Mirg*) in control, *Meg3* KD, and KOs (*IG-DMR^matΔ^*, *Rian^Δ/Δ^*, and *Mirg^Δ/Δ^*) ESCs respectively. (**C**) Rostral *Hox* gene *Hoxa5* is significantly down-regulated in the *Meg3* KD line, whereas the expression of *Hoxa5* is comparable between *Rian^Δ/Δ^* and *Mirg^Δ/Δ^* when compared to the controls. Conversely, the expressions of progenitor gene *Pax6*, as well as caudal *Hox* gene *Hoxc8*, are significantly up-regulated in the *Meg3* KD line, while their expressions are restored between *Rian^Δ/Δ^* and *Mirg^Δ/Δ^* when compared to the controls. (FC: fold-change; error bars represent SD, n = 3\~5, \* p-value\<0.05, \*\* p-value\<0.01 by Student's *t*-test). (**D**) Summary of the functions of lncRNAs from the imprinted *Dlk1-Dio3* locus in ESC\~MNs. *Meg3* and other lncRNAs from the *Dlk1-Dio3* locus are directly activated by MN-TFs (i.e., Lhx3 and Isl1) and RAR, leading to enrichment of *Meg3* in the rostral segment of postmitotic MNs. One major function of *Meg3* and other lncRNAs from the *Dlk1-Dio3* locus is to stimulate Ezh2/Jarid2 interactions. Loss of these lncRNAs compromises the H3K27me3 epigenetic landscape and leads to aberrant expressions of progenitor and caudal *Hox* genes in postmitotic MNs. Our model illustrates that the lncRNAs of the imprinted *Dlk1-Dio3* locus (*Meg3* particularly) play a critical role in maintaining postmitotic MN cell fate by repressing progenitor genes, and that they shape MN subtype identity by regulating *Hox* genes.](elife-38080-fig8){#fig8}

Discussion {#s3}
==========

Although mammalian genomes encode tens of thousands of lncRNAs, only less than a hundred have been shown to play critical roles in gene regulation in vitro. Consequently, the in vivo functions of the vast majority of lncRNAs remain to be vigorously tested. Strikingly, 40% of lncRNAs are expressed specifically in the central nervous system (CNS), which makes it one of the best systems for uncovering the physiological functions of lncRNAs ([@bib4]; [@bib67]). In this study, we identified a series of novel and/or uncharacterized lncRNAs that exhibit precisely regulated temporal and spatial expression patterns during MN development. Here, we focused on characterizing lncRNAs located in the imprinted *Dlk1-Dio3* locus for three reasons: (1) this locus is conserved between human and mouse ([@bib51]; [@bib50]); (2) several studies have highlighted that *Meg3* might function as a tumor suppressor ([@bib102]; [@bib105]); and (3) a previous report indicates that the paternally-expressed coding gene *Dlk1* has an unexpected function in determining MN subtype diversification ([@bib65]), which prompted us to examine whether the MN-enriched lncRNAs in the same locus also participate in MN cell fate determination.

Functional perspectives of lncRNAs in MNs {#s3-1}
-----------------------------------------

Although lncRNAs derived from the *Dlk1-Dio3* locus are highly expressed in the CNS, their functions during neural development are largely unknown ([@bib95]; [@bib101]; [@bib107]). Upon KD of *Meg3* (a *Dlk1-Dio3* locus-derived lncRNA), we uncovered that: 1) many adjacent progenitor genes were significantly up-regulated; and 2) the rostral *Hox* genes were significantly down-regulated, with a concomitant increased expression of caudal *Hox* genes in ESC\~MNs. This phenotype was recapitulated in *IG-DMR^matΔ^* embryos, in which Hoxc8 expression is expanded in otherwise Hoxa5^on^ MNs. Several reports have identified that certain lncRNAs can shape the *Hox* epigenetic landscape by *cis* and *trans* modulation ([@bib21]; [@bib78]; [@bib94]). In addition, we recently uncovered that a novel *trans* Hox-miRNA circuit can filter *Hox* transcription noise and prevents precocious protein expression to confer robust individual MN identity ([@bib48]). Here, we have now added the *Meg3* imprinted lncRNA to that list as a novel *trans*-acting lncRNA that maintains the *Hox* epigenetic landscape, most likely by recruiting Jarid2 to the PRC2 complex. Given that *Meg3* is also highly expressed in ESCs ([@bib35]; [@bib64]), we plan to generate a targeted *Meg3* floxed allele mouse line in the future that will allow us to specifically knockout *Meg3* in MNs and recover the potential function of *Meg3* in cell-type specific contexts.

A fail-safe mechanism to guard MN epigenetic landscape {#s3-2}
------------------------------------------------------

Why do MNs deploy lncRNA-mediated strategy to maintain postmitotic cell fate by inhibiting progenitor genes and regulating Hox boundaries? The dynamic role of lncRNAs in modulating PRC2 function is well documented; ranging from recruitment, complex loading and activity control to gene targeting ([@bib24]; [@bib38]). A recent study of *Drosophila Hox* genes revealed that epigenetic H3K27me3 chromatin modification functions as a legitimate carrier of epigenetic memory ([@bib14]), providing compelling evidence for a physiologically significant role of chromatin modification in epigenetic inheritance. Nonetheless, the epigenetic memory carried by H3K27me3 in a postmitotic cell may still be overridden by H3K27me3-opposing demethylases ([@bib14]). Our RNA-seq data revealed that two prominent H3K27me3 demethylases, *Kdm6a (Utx)* and *Kdm6b (Jmjd3)*, are reactivated in postmitotic MNs (data not shown). Although the function of H3K27me3 demethylase reactivation in postmitotic MNs remains unknown, these findings raise the possibility that the epigenetic memory of the H3K27me3 landscape in postmitotic MNs might still need to be 'actively' maintained to counterbalance H3K27me3 demethylase activity. Enrichment of postmitotic MN lncRNAs might therefore bridge and scaffold the PRC2/Jarid2 interaction and activity to maintain MN epigenetic memory by repressing progenitor genes and also carve MN subtype identity by repressing caudal *Hox* genes ([Figure 8D](#fig8){ref-type="fig"}).

Although we observed a complete 100% penetrance of Hoxa5-c8 cell fate switch in the rostrobrachial segments and an increase co-expression of Irx3^on^Hb9^on^ cells in the *IG-DMR^matΔ^* embryos ([Figures 5](#fig5){ref-type="fig"} and [6](#fig6){ref-type="fig"}), ectopic Pax6 was manifested at partial penetrance (45%, 5 in the 11 mutants) and several caudal Hox protein (including Hox9 and 10) were not shown to display significant change in vivo ([Figure 5](#fig5){ref-type="fig"} and [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}), consistent with the finding that removal of *Ezh2* from MN progenitors has no detectable impact on segmental Hox expression in the spinal cord (Hoxc6 and Hoxc9) ([@bib30]). This result also suggests that a compensatory PRC1-mediated function in vivo might make up for the loss of *Meg3*-mediated epigenetic maintenance in segmental MNs ([@bib30]; [@bib60]). Our results are not entirely unexpected as many potent miRNA/lncRNA KO mice reflect either only partial phenotype penetrance ([@bib45]; [@bib47]; [@bib63]), or more severe phenotypes upon genetic or environmental stresses ([@bib98]). Moreover, many miRNAs/TFs function as repressors to silence progenitor/neighboring interneuron genes ([@bib9]; [@bib84]), they may also constitute a coherent loop with lncRNAs to safeguard the terminal postmitotic cell fate with a fail-safe control.

PRC2-lncRNA regulation in MNs {#s3-3}
-----------------------------

A previous study reported that hypomorphic *Suz12^-/-^* ESCs maintained with a low amount of H3K27me3 can differentiate into MNs, albeit with a significant increase in the expression of caudal *Hoxc6* and *Hoxa7* compared to wild-type cells ([@bib60]). Interestingly, another study found that several PRC2 mutant ESC lines that maintain varying levels of H3K27me3 allowed for proper temporal activation of lineage genes during directed differentiation of ESCs to MNs, but only a subset of the genes that function to specify other lineages were not repressed in these cells ([@bib90]). This outcome might not be surprising since other epigenetic marks, such as DNA methylation, might safeguard gene expression throughout differentiation ([@bib54]). In this study, up-regulated genes in spinal MNs upon loss of *Meg3-Rian-Mirg* exhibited 50% concordance (3953/7474) with the up-regulated genes in *Suz12^-/-^* spinal MNs (data not shown). Together, these results strongly endorse the critical function of PRC2/lncRNA in perpetuating the postmitotic cell fate of cervical Hoxa5^on^ MNs.

Given that lncRNAs such as *Hotair* are proposed to scaffold the PRC2 complex and guide it to specific genome loci ([@bib78]; [@bib79]; [@bib92]), it is tantalizing to hypothesize that *Meg3* might manifest the dual functions of scaffolding the PRC2/Jarid2 complex and guiding it to specific loci in different cell contexts. This scenario could partially explain why only subsets of genes in an MN context are particularly sensitive to the loss of ncRNAs from the *Dlk1-Dio3* locus. Inspired by the salient Hox phenotype exhibited in the *IG-DMR^matΔ^* mutants, we envisage using *Meg3* as a paradigm to decipher the *Meg3*-protein-DNA interactome by ChIRP-seq/ChIRP-MS, thereby allowing us to decipher the detailed targeting mechanism of PRC2/Jarid2 involved in maintaining the epigenetic landscape during embryonic development ([@bib12]). Interestingly, *Hotair ^-/-^* mice also show partial penetrance of homeotic transformation and increased expression of *Meg3* ([@bib45]). This finding prompts us to test in the future the hypothesis that *trans*-acting lncRNAs might have an unexpected redundant role for PRC2 complex scaffolding and targeting despite having no primary sequence conservation. Generating compound lncRNA mutants that can scaffold the PRC2/Jarid2 complex will shed light on this topic.

Regulatory mode of *Meg3* for the PRC2/Jarid2 complex {#s3-4}
-----------------------------------------------------

The role of lncRNAs in modulating PRC2 function is well documented, but very dynamic; from recruitment, complex loading and activity control to gene targeting ([@bib24]; [@bib38]). Mammalian PRC2 binds thousands of RNAs in vivo, and it is a good system for studying the recruitment of chromatin modifying factors by RNA. Recent studies suggest that lncRNAs facilitate JARID2-PRC2 interactions on chromatin and propose a mechanism by which lncRNAs contribute to PRC2 recruitment ([@bib16]; [@bib35]; [@bib36]). Other studies have provided an alternative working model, whereby the JARID2 and PRC2 sub-complex have different RNA-binding affinities and RNA binding to EZH2 inhibits its methyltransferase activity in a concentration- and binding affinity-dependent manner. Surprisingly, the binding of RNA attenuates the methyltransferase activity of EZH2, which allows JARID2 to relieve the repressive effect of RNA on PRC2 catalysis ([@bib13]; [@bib23]; [@bib22]). Both these models differ but are not contradictory, as both models emphasize the role of RNA in the PRC2/JARID2 complex, albeit with different binding affinities and modes of action. Interestingly, a recent report further uncovered that *MEG3* binds to chromatin sites with GA/GT-rich sequences through RNA--DNA triplex formation ([@bib33]). This finding raises the possibility that the GA-rich motif alone is not sufficient in all cell types ([@bib11]). Future systematic *Meg3* ChIRP-seq analyses, together with Ezh2/Jarid2 CLIP-seq, at all stages of ESC\~MN differentiation might aid in identifying the context-dependent/independent lncRNA-mediated PRC2 targeting strategy.

Combinatorial and individual roles of the *Meg3-Rian-Mirg* lncRNA cluster {#s3-5}
-------------------------------------------------------------------------

There have been multiple efforts to dissect the functions of the maternally-expressed lncRNAs in the *Meg3-Rian-Mirg* locus over the past decade ([@bib62]; [@bib87]; [@bib88]; [@bib106]), but definitive results remain elusive. The difficulty is mainly attributable to two major hurdles; namely that 1) there are many DMRs that control imprinting status in upstream, promoter, and exon regions of *Meg*3, and 2) *Meg3* might function *in cis* to regulate its imprinting status ([@bib56]; [@bib69]). Specifically, two *Meg3* knockout mouse lines have previously been generated either by deletion of the first five exons plus approximately 300 bp of the adjacent upstream promoter region of *Meg3* (\~5.9 kb) ([@bib106]) or by deletion of \~10 kb that includes the *Meg3*-DMR region plus the first five exons of *Meg3* ([@bib88]). Both of these *Meg3* KO lines also manifested loss of maternal *Rian* and *Mirg* lncRNA expression. However, whereas the \~5.9 kb *Meg3* KO line ([@bib106]) exhibited perinatal lethality, the \~10 kb *Meg3* KO line ([@bib88]) presented a much milder phenotype in that the mice were born alive and lived up to 4 weeks after birth. We also found that expression of most, if not all, lncRNAs in the *Meg3-Rian-Mirg* locus are reduced upon *Meg3* KD and in *IG-DMR^MatΔ^* mutants. Therefore, it remains technically challenging to obtain a specific *Meg3* KO without abrogating the expression levels of downstream lncRNAs.

Although we have further shown here that *Meg3* acts as a scaffold for the PRC2/Jarid2 complex, it is still possible that *Rian* and *Mirg* could independently and/or synergistically function with *Meg3* to contribute to the Hox-mediated MN subtype switching we observed in the *IG-DMR^MatΔ^* mutants. To investigate this possibility, we instead generated two independent targeted deletion ESC lines of *Meg3* downstream lncRNAs, *Rian^Δ/Δ^* and *Mirg^Δ/Δ^*. Consistent with previous results ([@bib31]; [@bib40]), deletions of these downstream lncRNAs show less profound phenotype than upstream *Meg3*. Our results reveal that the progenitor gene *Pax6* and caudal *Hox* genes in these two KO ESC\~MNs are relatively unaffected when compared to *Meg3* KD. Interestingly, *Mirg* KO embryos seem to have a less severe phenotype, and no observed homeotic transformation has been reported ([@bib40]). Furthermore, our results indicate that *Mirg* does not bind to Ezh2/Suz12/Jarid2 ([Figure 3A](#fig3){ref-type="fig"}). Thus, it is likely that *Meg3* might be the major contributor to MN subtype specification via epigenetic regulation. In this study, we did not delete lncRNA *Rtl1as* in the *Dlk1-Dio3* locus, as the deletion of *Rtl1as* simultaneously compromises paternal *Rtl1* expression ([@bib15]). Therefore, we still can not completely rule out the possible synergistic ncRNA effects accounting for MN phenotype we observed in the *IG-DMR^MatΔ^* embryos. Since lncRNAs are emerging as important modulators of gene regulatory networks and as epigenetic regulators of gene expression, we are endeavoring to systematically generate individual lncRNA KO embryos in the *Meg3-Rain-Mirg* locus by a CRISPR-Cas9-mediated approach. We anticipate that a detailed map of individual and synergetic lncRNA/miRNA functions during neural development attributable to this imprinted locus will be uncovered in the near future.

Versatile functions of *Meg3* in development and disease {#s3-6}
--------------------------------------------------------

Consistent with the imprinting status of the *DLK1-DIO3* locus in humans, epimutations (hypermethylations) and microdeletions affecting *IG-DMR* and/or *MEG3-DMR* of maternal origin result in a unique human phenotype manifested as a small bell-shaped thorax, coat-hanger-like appearance of the ribs, abdominal wall defects, placentomegaly and polyhydramnios. One hallmark of patients with this disease, termed 'Kagami-Ogata syndrome' (KOS) ([@bib34]; [@bib69]), is that nearly all of them display delayed gross motor development. It is currently unknown why epimutations and microdeletions of maternal *IG-DMR* give rise to this phenotype.

In our *IG-DMR^matΔ^* embryos, we previously observed extra ossification at the sites where the 6^th^ to 8^th^ ribs attach to the sternum, similar to the malformed thorax in KOS patients ([@bib51]). Interestingly, this phenotype was also observed in *Hox5* mutant mouse embryos ([@bib61]). Here, we uncovered that two isoforms of the *Meg3* imprinted lncRNA are enriched in embryonic MNs and confer the fidelity of the epigenetic landscape for the Hoxa5-Hoxc8 boundary of MN subtypes. Loss of *Meg3* in vitro and in vivo abrogates the Hoxa5^on^ MNs in the brachial region, with a concomitant increase of ectopic Hoxc8^on^ subtypes. This switch leads to erosion of Hoxa5^on^ motor axon arborization in the proximal muscles. As *Meg3* expression is also highly enriched in somites, we suggest that impairment of the Hox boundary mediated by *Meg3* in the spinal cord and ribs might account for the bell-shaped thorax and motor deficit in KOS patients, potentially identifying a new therapeutic target for KOS patients.

In addition to the roles of the *Meg3* imprinted lncRNA uncovered by our study, other reports have also emphasized *Meg3* as being important for proper growth and development and to be a putative tumor suppressor that activates p53 and inhibits cell proliferation ([@bib88]; [@bib102]; [@bib105]). Moreover, aberrant repression of *Meg3* and other maternally-expressed lncRNAs from the *DLK1-DIO3* imprinting cluster is present in several induced pluripotent stem cell (iPSC) lines. This scenario might lead to failure of these iPSCs to form viable mice ([@bib86]) or to efficiently differentiate into neural lineage cells ([@bib64]), raising the possibility that *Meg3* might be involved in a broad spectrum of developmental processes and disease contexts. Thus, our exploration of *Meg3* may also suggest new avenues for treating other diseases, such as cancers, as well as in elucidating the reprogramming mechanism of iPSCs.

Materials and methods {#s4}
=====================

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\      Designation                 Source or reference                                             Identifiers                                                      Additional information
  (species) or\                                                                                                                                                                   
  resource                                                                                                                                                                        
  ------------------ --------------------------- --------------------------------------------------------------- ---------------------------------------------------------------- ------------------------
  Antibody           Rabbit polyclonal\          Abcam                                                           Cat\# ab14555,\                                                  ICC (1:2000)
                     anti-Lhx3                                                                                   RRID:[AB_301332](https://scicrunch.org/resolver/AB_301332)       

  Antibody           Rabbit polyclonal\          Abcam                                                           Cat\# ab16645,\                                                  ICC (1:20000)
                     anti-Foxp1                                                                                  RRID:[AB_732428](https://scicrunch.org/resolver/AB_732428)       

  Antibody           Mouse monoclonal\           DSHB                                                            Cat\# 39.4D5,\                                                   ICC (1:1000)
                     anti-Isl1(2)                                                                                RRID:[AB_2314683](https://scicrunch.org/resolver/AB_2314683)     

  Antibody           Rabbit polyclonal\          Sigma-Aldrich                                                   Cat\# HPA029319,\                                                ICC (1:5000)
                     anti-Hoxa5                                                                                  RRID:[AB_10601430](https://scicrunch.org/resolver/AB_10601430)   

  Antibody           Rabbit polyclonal\          Jeremy Dasen (NYU)                                                                                                               ICC (1:16000)
                     anti-Hoxa5                                                                                                                                                   

  Antibody           Guinea pig polyclonal\      Jun-An Chen\                                                    AB_2744661                                                       ICC (1:20000)
                     pig anti-Hoxa5              (Academia Sinica)                                                                                                                

  Antibody           Mouse monoclonal\           DSHB                                                            Cat\# PCRP-HOXC8-1D3,\                                           ICC (1:1000)
                     anti-Hoxc8                                                                                  RRID:[AB_2618723](https://scicrunch.org/resolver/AB_2618723)     

  Antibody           Rabbit polyclonal\          Sigma-Aldrich                                                   Cat\# HPA028911,\                                                ICC (1:5000)
                     anti-Hoxc8                                                                                  RRID:[AB_10602236](https://scicrunch.org/resolver/AB_10602236)   

  Antibody           Rabbit polyclonal\          Thomas Jessell\                                                 Cat\# C115,\                                                     ICC (1:2000)
                     anti-Pea3                   (Columbia University)                                           RRID:[AB_2631446](https://scicrunch.org/resolver/AB_2631446)     

  Antibody           Guinea pig polyclonal\      Thomas Jessell\                                                 Cat\# CU822,\                                                    ICC (1:2000)
                     anti-Scip                   (Columbia University)                                           RRID:[AB_2631303](https://scicrunch.org/resolver/AB_2631303)     

  Antibody           Sheep polyclonal\           AbD Serotec                                                     Cat\# 4745--1051,\                                               ICC (1:1000)
                     anti-GFP                                                                                    RRID:[AB_619712](https://scicrunch.org/resolver/AB_619712)       

  Antibody           Rabbit polyclonal\          Thomas Jessell\                                                                                                                  ICC (1:16000)
                     anti-Irx3                   (Columbia University)                                                                                                            

  Antibody           Rabbit anti-Pax6            Covance                                                         Cat\# PRB-278P,\                                                 ICC (1:300)
                                                                                                                 RRID:[AB_291612](https://scicrunch.org/resolver/AB_291612)       

  Antibody           Guinea pig\                 Hynek Wichterle\                                                                                                                 ICC (1:1000)
                     polyclonal anti-Hb9         (Columbia University)                                                                                                            

  Antibody           Mouse monoclonal\           DSHB                                                            Cat\# 81.5C10,\                                                  ICC (1:200)
                     anti-Hb9                                                                                    RRID:[AB_2145209](https://scicrunch.org/resolver/AB_2145209)     

  Antibody           Mouse monoclonal\           DSHB                                                            Cat\# 74.5A5,\                                                   ICC (1:100)
                     anti-Nkx2.2                                                                                 RRID:[AB_53179](https://scicrunch.org/resolver/AB_53179)         

  Antibody           Rabbit polyclonal\          Millipore                                                       Cat\# AB9610,\                                                   ICC (1: 20000)
                     anti-Olig2                                                                                  RRID:[AB_570666](https://scicrunch.org/resolver/AB_570666)       

  Antibody           Goat polyclonal\            Santa Cruz                                                      Cat\# sc-46135,\                                                 ICC (1:1000)
                     anti-Hoxc6                                                                                  RRID:[AB_2119751](https://scicrunch.org/resolver/AB_2119751)     

  Antibody           Rabbit polyclonal\          Thomas Jessell\                                                 Cat\# Rabbit one\                                                ICC (1:1000)
                     anti-Hoxc9                  (Columbia University)                                           anti-HoxC9,\                                                     
                                                                                                                 RRID:[AB_2631312](https://scicrunch.org/resolver/AB_2631312)     

  Antibody           Goat polyclonal\            Santa Cruz                                                      Cat\# sc-33005,\                                                 ICC (1:1000)
                     anti-Hoxd10                                                                                 RRID:[AB_648462](https://scicrunch.org/resolver/AB_648462)       

  Antibody           Mouse monoclonal\           Millipore                                                       Cat\# 17--662,\                                                  WB (1:2000);\
                     anti-Ezh2                                                                                   RRID:[AB_1977568](https://scicrunch.org/resolver/AB_1977568)     RIP/ChIP/IP (2 μg)

  Antibody           Rabbit polyclonal\          Novus                                                           Cat\# NB10\                                                      WB (1:1000);\
                     anti-Jarid2                                                                                 0-2214,\                                                         RIP/ChIP (5 μg)
                                                                                                                 RRID:[AB_10000529](https://scicrunch.org/resolver/AB_10000529)   

  Antibody           Rabbit polyclonal\          Abcam                                                           Cat\# ab12073,\                                                  WB (1:3000);\
                     anti-Suz12                                                                                  RRID:[AB_442939](https://scicrunch.org/resolver/AB_442939)       RIP (2.5 μg)

  Antibody           Mouse monoclonal\           Abcam                                                           Cat\# ab24834,\                                                  WB (1:1000)
                     anti-Histone H3                                                                             RRID:[AB_470335](https://scicrunch.org/resolver/AB_470335)       

  Antibody           Mouse monoclonal\           Abcam                                                           Cat\# ab6002,\                                                   ChIP (2 μg)
                     anti-H3K27me3                                                                               RRID:[AB_305237](https://scicrunch.org/resolver/AB_305237)       

  cell line          Mouse: *Hb9::GFP* ESC       PMID:[12176325](https://www.ncbi.nlm.nih.gov/pubmed/12176325)                                                                    Dr. Hynek Wichterle\
                                                                                                                                                                                  (Columbia University)

  Cell line          Mouse: *Meg3* KD H6 ESC     this paper                                                                                                                       

  Cell line          Mouse: *Meg3* KD K4 ESC     this paper                                                                                                                       

  Cell line          Mouse: *Meg3* KD I6 ESC     this paper                                                                                                                       

  Cell line          Mouse: *iMeg3^v1^* ESC      this paper                                                                                                                       

  Cell line          Mouse: *iMeg3^v5^* ESC      this paper                                                                                                                       

  Cell line          Mouse: *IG-DMR^matΔ^* ESC   this paper                                                                                                                       

  Cell line          Mouse: *Rian^Δ/Δ^* ESC      this paper                                                                                                                       

  Cell line          Mouse: *Mirg^Δ/Δ^* ESC      this paper                                                                                                                       

  Genetic reagent\   *Hb9::GFP*                  PMID:[12176325](https://www.ncbi.nlm.nih.gov/pubmed/12176325)                                                                    Dr. Hynek Wichterle\
  (*M. musculus*)                                                                                                                                                                 (Columbia University)

  Genetic reagent\   *IG-DMR^matΔ^*              PMID:[12937418](https://www.ncbi.nlm.nih.gov/pubmed/12937418)                                                                    Dr. Ann Fergusson\
  (*M. musculus*)                                                                                                                                                                 Smith (University\
                                                                                                                                                                                  of Cambridge)

  Commercial\        Biotin RNA Labeling Mix     Roche                                                           11685597910                                                      
  assay or kit                                                                                                                                                                    

  Commercial\        Oligo Clean and\            Zymo Research                                                   D4060                                                            
  assay or kit       Concentrator                                                                                                                                                 

  Commercial\        RNA-Binding Protein\        Millipore                                                       17--700                                                          
  assay or kit       Immunoprecipitation Kit                                                                                                                                      

  Commercial\        TruSeq ChIP Library\        Illumina                                                        IP-202--1012                                                     
  assay or kit       Preparation Kit                                                                                                                                              

  Software,\         Imaris 8.4.0                                                                                RRID:[SCR_007370](https://scicrunch.org/resolver/SCR_007370)     
  algorithm                                                                                                                                                                       
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

  *Meg3* in situ hybridization probe primer                                                 
  ------------------------------------------- --------------------------------------------- ----------------------
  *Meg3*                                      GAGTAATACGACTCACTATAGGGAACGTGTTGTGCGTGAAGTC   AACGTGTTGTGCGTGAAGTC

  List of primers for quantitative RT-PCR analyses                              
  -------------------------------------------------- -------------------------- ----------------------------
  *Meg3^v1^*                                         GCTTCTCGAGGCCTGTCTAC       GAACCTGAGCACAACAGCAA
  *Meg3^v5^*                                         GAGGGACAAGCGACAAAGAG       CAGATGAACACGAGCACAGA
  *Meg3^v1(exon1\~5)^*                               GCTGCTTTCCTTCCTCACCT       TTTTCTCCTCAGCCCTTTGA
  *Meg3^v1(exon1\~2)^*                               GCTTCTCGAGGCCTGTCTAC       GAACCTGAGCACAACAGCAA
  *Meg3^v5(exon2\~3)^*                               TGCACCTCTACCTCCTGAGC       CAAGGTTTGAACCCCAGAGA
  *Meg3^v5\~v1-1^*                                   GCCCAAGTCTGGTAGCATGT       TACCTCAGCCATAGCCTGGT
  *Meg3^v5\~v1-2^*                                   GGGTGAATTGGCATTGATTT       GGGGTAGACAACCTGGCTTT
  *Rian*                                             CTTCCAGGGTGAATTTTCCTAA     TATGGCCAAGCAATTCTGC
  *Rian^sgΔ^*                                        TGGATATCCTGCAAGTCGGC       GAACAGAGCTGACCGTGACA
  *Mirg*                                             ACGACAACCGACAACAAAGA       GAAAGCCAAGAGCAGAAACC
  *Dlk1*                                             CGGGAAATTCTGCGAAATAG       TGTGCAGGAGCATTCGTACT
  *Dio3*                                             GAGTCCTGCTGCTTTTGTGTT      CCCTCTTCCACCCCTTTTT
  *Hb9*                                              GTTGGAGCTGGAACACCAGT       GCTCTTTGGCCTTTTTGCT
  *Irx3*                                             GTCCAAGCGGGGAATTTG         AGCCCAAGATCTGGTCACTG
  *Pax6*                                             GGACTGAGCTGACCCAAGAG       CAAGAGGGGAGGGGAAGTAG
  *Hoxa1*                                            ACCAAGAAGCCTGTCGTTCC       TAGCCGTACTCTCCAACTTTCC
  *Hoxa2*                                            CCTGGATGAAGGAGAAGAAGG      GTTGGTGTACGCGGTTCTCA
  *Hoxa3*                                            TCAAGGCAGAACACTAAGCAGA     ATAGGTAGCGGTTGAAGTGGAA
  *Hoxa4*                                            TGTACCCCTGGATGAAGAAGAT     AAGACTTGCTGCCGGGTATAG
  *Hoxa5*                                            TGTACGTGGAAGTGTTCCTGTC     GTCACAGTTTTCGTCACAGAGC
  *Hoxa6*                                            ACCGACCGGAAGTACACAAG       AGGTAGCGGTTGAAGTGGAAT
  *Hoxa7*                                            GAAGCCAGTTTCCGCATCTAC      CTTCTCCAGTTCCAGCGTCT
  *Hoxa9*                                            TCCCTGACTGACTATGCTTGTG     ATCGCTTCTTCCGAGTGGAG
  *Hoxa10*                                           GAAGAAACGCTGCCCTTACAC      TTTCACTTGTCTGTCCGTGAG
  *Hoxa13*                                           GCTGCCCTACGGCTACTTC        GCGGTGTCCATGTACTTGTC
  *Hoxb1*                                            TTCGACTGGATGAAGGTCAA       GGTGAAGTTTGTGCGGAGAC
  *Hoxb2*                                            ACCAAGAAACCCAGCCAATC       AGCAGTTGCGTGTTGGTGTAG
  *Hoxb3*                                            CAACTCCACCCTCACCAAAC       ACCACAACCTTCTGCTGTGC
  *Hoxb4*                                            CTGGATGCGCAAAGTTCAC        GACCTGCTGGCGAGTGTAG
  *Hoxb5*                                            AGGGGCAGACTCCACAGATA       CTGGTAGCGAGTATAGGCGG
  *Hoxb6*                                            AGCAGAAGTGCTCCACGC         TAGCGTGTGTAGGTCTGGCG
  *Hoxb7*                                            CGAGAGTAACTTCCGGATCTACC    TTTCTCCAGCTCCAGGGTCT
  *Hoxb8*                                            ACACAGCTCTTTCCCTGGATG      GGTCTGGTAGCGACTGTAGGTC
  *Hoxb9*                                            AGGAAGCGAGGACAAAGAGAG      TGGTATTTGGTGTAGGGACAGC
  *Hoxb13*                                           ATTCTGGAAAGCAGCGTTTG       CTTGCTATAGGGAATGCGTTTT
  *Hoxc4*                                            AGCAAGCAACCCATAGTCTACC     GCGGTTGTAATGAAACTCTTTCTC
  *Hoxc5*                                            CACAGATTTACCCGTGGATGAC     CTTTCTCGAGTTCCAGGGTCT
  *Hoxc6*                                            TAGTTCTGAGCAGGGCAGGA       CGAGTTAGGTAGCGGTTGAAGT
  *Hoxc8*                                            GTAAATCCTCCGCCAACACTAA     CGCTTTCTGGTCAAATAAGGAT
  *Hoxc9*                                            GCAAGCACAAAGAGGAGAAGG      CGTCTGGTACTTGGTGTAGGG
  *Hoxc10*                                           CGGATAACGAAGCTAAAGAGGA     GCGTCTGGTGTTTAGTATAGGG
  *Hoxc12*                                           GACTCCAGTTCGTCCCTACTCA     TGAACTCGTTGACCAGAAACTC
  *Hoxc13*                                           GGAAGTCTCCCTTCCCAGAC       GCGTACTCCTTCTCTAGCTCCTT
  *Hoxd1*                                            ACAGCACTTTCGAGTGGATGA      AGGGCTTGTGGCTCCATATT
  *Hoxd3*                                            CTACCCTTGGATGAAGAAGGTG     TCAGACAGACACAGGGTGTGA
  *Hoxd4*                                            CTACCCTTGGATGAAGAAGGTG     TTCTAGGACTTGCTGTCTGGTG
  *Hoxd8*                                            GCTCGTCTCCTTCTCAAATGTT     GCGACTGTAGGTTTGTCTTCCT
  *Hoxd9*                                            CAGCAACTTGACCCAAACAAC      TGGTATTTGGTGTAGGGACAGC
  *Hoxd10*                                           CTGAGGTTTCCGTGTCCAGT       CAATTGCTGGTTGGAGTATCAG
  *Hoxd11*                                           ACACCAAGTACCAGATCCGC       AGTGAGGTTGAGCATCCGAG
  *Hoxd12*                                           CTTCACTGCCCGACGGTA         TGCTTTGTGTAGGGTTTCCTCT
  *Hoxd13*                                           GGAACAGCCAGGTGTACTGTG      GTAAGGCACCCTTTTCTTCCTT
  *Neurog2*                                          GACATTCCCGGACACACAC        AGCTCCTCGTCCTCCTCCT
  *Isl1*                                             AGCTGGAGACCCTCTCAGTC       TGCTTCTCGTTGAGCACAGT
  *Gapdh*                                            AGGCCGGTGCTGAGTATGTC       GCCTGCTTCACCACCTTCT
  *Rnu1*                                             GGGAGATACCATGATCACGAAGGT   CCACAAATTATGCAGTCGAGTTTCCC
  *Malat1*                                           CATGGCGGAATTGCTGGTA        CGTGCCAACAGCATAGCAGTA
  *Kcnq1ot1*                                         CCTTCCTTGTGCTTTGACCC       GATCGCCTAAGACCATCGGA

  sgRNA sequences used in this work   
  ----------------------------------- -----------------------
  sg-*Rian* N1                        TCCATGGTTCACTGAAGGCC
  sg-*Rian* C1                        GGCAAGGTTAGGATTATACAA
  sg*-Mirg* U                         GCTAAGATATTCGTCACCTA
  sg*-Mirg* D                         CAGCTTGGTCACGACTCGGC

  List of primers for CRISPR deletion genotyping/sequencing                          
  ----------------------------------------------------------- ---------------------- ----------------------
  *Rian* WT                                                   AACCATGGCATCTGTGTGAA   CAAAAATCAACCGCCCTCTA
  *Rian* KO                                                   GATGTGACTGCTTTGAGGCA   GTGCTCCAGAAGCCGAAAAG
  *Mirg* WT                                                   CCACTCTCCTCAGCATCCAT   GAGCAGTTTGAGAGGCCCTA
  *Mirg* KO                                                   CCACTCTCCTCAGCATCCAT   GCTCTGGGGAGAACAGTGAG

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Published ChIP-Seq data summary (related to [Figure 2D, G and H](#fig2){ref-type="fig"}, [Figure 4---figure supplement 1A,B](#fig4s1){ref-type="fig"})                
  -------------------------------------------------------------------------------------------------------------------------------------------------------- ------------ ------------
  Induced V5-tagged\                                                                                                                                       GSM782847    ([@bib59])
  Lhx3 (iLhx3-V5) in\                                                                                                                                                   
  iNIL3-induced motor neurons (Day 4)                                                                                                                                   

  Isl1/2 in iNIL3-induced motor neurons (Day 4)                                                                                                            GSM782848    ([@bib59])

  H3K4me3                                                                                                                                                  GSM1468401   ([@bib66])

  H3K27ac_day6                                                                                                                                             GSM2098385   ([@bib77])

  ATAC_seq_day6                                                                                                                                            GSM2098391   ([@bib77])

  RAR_Day2 + 8hrsRA                                                                                                                                        GSM482750    ([@bib53])

  Pol2-S5P_Day2 + 8 hr                                                                                                                                     GSM981593    ([@bib53])

  H3K27me3.MN.WT                                                                                                                                           GSM1468398   ([@bib66])

  EZH2.MN.WT                                                                                                                                               GSM1468404   ([@bib66])
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Mouse ESC culture and MN differentiation {#s4-1}
----------------------------------------

ESCs were cultured and differentiated into spinal MNs as previously described ([@bib96]; [@bib97]). Cells were trypsinized and collected for FACS at day seven to purify GFP^on^ neurons for qPCR analysis and strand-specific RNA-seq when required. All cell lines used in this study are subject to regular mycoplasma test.

Mouse crosses and in vivo studies {#s4-2}
---------------------------------

The *IG-DMR^matΔ^* mouse strain is described in [@bib50]. Female mice carrying the deletion were mated with wild type C57BL6/J male mice to generate embryos with the maternally-inherited deletion. Mice were mated at the age of 8\~12 weeks and the embryo stage was estimated as E0.5 when a copulation plug was observed. Embryos were analyzed between E9.5\~E13.5. All of the live animals were kept in an SPF animal facility, approved and overseen by IACUC Academia Sinica.

Knockdown of *Meg3* in mouse ES cells by shRNA {#s4-3}
----------------------------------------------

The *Meg3* HuSH-29 shRNA plasmids (Origene, cat. No. TG501330) and non-effective scrambled sequence (TR20003) were used to create stable knockdown lines of *Meg3* within the *Hb9::GFP* ESCs. We used two different shRNA sequences to knockdown *Meg3*. Additionally, stable infected ESCs were selected by puromycin. Single ESC clones with good morphology and only presenting knockdown efficiencies \>90% were picked for further expansion and characterization.

Expression analysis {#s4-4}
-------------------

ESCs or embryoid bodies were harvested for total RNA isolation by Trizol (Thermo Scientific). For qPCR analysis, total RNA from each sample was reverse transcribed with Superscript III (Thermo Scientific). One-tenth of the reverse transcription reaction was used for subsequent qPCR reactions, which were performed in triplicate with three independent experimental samples on a LightCycler480 Real Time PCR instrument (Roche) using SYBR Green PCR mix (Roche) for each gene of interest. *Gapdh* was used as a control for normalization. For GeneChip expression analysis, RNA was purified and amplified using the Qiagen RNAeasy kit and a one-color Low Input Quick Amp Labeling Kit (Agilent Genomics) and hybridized to a SurePrint G3 Mouse GE 8×60K Microarray. Differentially**-**expressed genes were defined by ranking all probes according to *Moderated t-test* and a fold-change threshold ≥2 (p\<0.001).

Chromatin immunoprecipitation (ChIP) {#s4-5}
------------------------------------

We followed a previously published protocol to perform ChIP-seq for ESC\~MNs ([@bib58]; [@bib66]). Four million cells were freshly dissociated from day 7 ESC\~MNs by trypsin and fixed in 10 mM HEPES pH 7.6, 1% formaldehyde, 15 mM NaCl, 0.15 mM EDTA and 0.075 mM EGTA for 15 min at room temperature. After fixation, cells were quenched with 1.25 M glycine. After an ice-cold PBS wash and low-speed centrifugation, nuclear extracts were suspended with ice-cold shearing buffer (SDS included) containing protease inhibitor and sheared using a Covaris M220 system to an average chromatin size of 200 bp. Chromatin was diluted with 2X IP buffer (2% NP-40, 200 mM NaCl in 10 mM Tris-HCl pH 8, 1 mM EDTA). Anti-H3K27me3 antibody was added to each ChIP (antibodies are listed in the resource table). Each ChIP reaction was performed in a rotator at 4°C overnight, followed by washing in wash buffer (25 mM HEPES pH 7.6, 1 mM EDTA, 0.1% N-Lauryl sarcosine, 1% NP-40, and 0.5 M LiCl) at room temperature. Cross-linking was reversed at 65°C for 16 hr with 5 M NaCl. Proteinase K was added to digest for another 2 hr at 56°C and DNA was extracted using the ChIP DNA Clean and Concentrator system (Zymo Research). We treated 1% of the input in parallel. Libraries were prepared according to the Illumina protocol and sequenced using an Illumina NextSeq Sequencing System.

Whole-mount staining, immunohistochemistry, and in situ hybridization {#s4-6}
---------------------------------------------------------------------

Immunohistochemistry was performed on 15 μm cryostat sections as described ([@bib9]). Primary antibodies used in this study are detailed in the resource table. Whole-mount antibody staining was performed as described ([@bib20]), and GFP-labeled motor axons were visualized in projections of a Zeiss Lightsheet Z.1 microscope (400--600 μm). Unless indicated otherwise, immunohistological data shown in figures are representative of n\>3 analyzed mutants. Images for control animals are from age-matched littermates. In situ hybridizations were performed as described previously ([@bib8]; [@bib9]) and in the Materials and Methods.

Subcellular RNA fractionation {#s4-7}
-----------------------------

We followed a previously published protocol to extract subcellular fractions of RNA ([@bib29]). We used TRIzol (Thermo Fisher Scientific) to extract RNA and perform reverse transcription (RT) with hexamer primers. *Gapdh* (mRNA in cytoplasm), *Rnu1* (snRNA in nucleus), and *Kcnq1ot1* (a known chromatin-associated lncRNA) were used as quality controls to verify fractionation.

RNA pull-down assay {#s4-8}
-------------------

In vitro-transcribed biotin-labelled RNAs were generated by the Biotin RNA Labeling Mix (Roche) and T7 RNA polymerase (Promega). Templates were treated with RNase-free DNase I (Promega) and the reaction mix was purified with Oligo Clean and Concentrator (D4060, Zymo Research). Biotinylated RNA (3 μg) was heated to 65°C for 10 min and then slowly cooled down to 4°C. After that, RNA structure buffer (10 mM Tris pH 7, 0.1 M KCl, 10 mM MgCl~2~) was added and the mix was shifted to room temperature for 20 min to allow proper secondary structure formation. Folded RNA was then mixed with 1 mg of ESC protein nuclear extract in RIP buffer (500 mM NaCl, 10 mM HEPES pH 7.5, 25% glycerol, 1 mM EDTA, and protease inhibitor) and incubated at 4°C for one hour. Twenty µL Dynabeads M-280 Streptavidin (Invitrogen) were added to each binding reaction and further incubated at room temperature for one hour. Beads were washed briefly five times and boiled in SDS buffer, and the retrieved protein was detected by standard Western blot analysis.

Co-immunoprecipitation (Co-IP) and Western blot {#s4-9}
-----------------------------------------------

For each IP, cells were harvested from a 10 cm dish and washed twice with ice cold PBS. Cell pellets were allowed to swell in twice the volume of cytoplasmic lysis buffer (50 mM NaCl, 10 mM HEPES-pH 7.5, 500 mM sucrose, 1 mM EDTA and protease inhibitors). Samples were incubated on ice for 10 min, followed by centrifugation at 2,000 rpm for 10 min. The cloudy supernatant cytoplasmic fraction was removed. After washing twice (50 mM NaCl, 10 mM HEPES-pH 7.5, 25% glycerol, 1 mM EDTA and protease inhibitors), the cell pellets were resuspended in the same volume of high salt buffer (500 mM NaCl, 10 mM HEPES-pH 7.5, 25% glycerol, 1 mM EDTA and protease inhibitors), and rotated for 30\~60 min at 4°C. Then cell pellets were centrifuged at 14,000 rpm for 10 min at 4°C. The supernatant was incubated overnight at 4°C with antibody and pre-cleared Protein-G beads (depending upon the antibody) to immunoprecipitate endogenous protein against the specific antibody used. We collected 10% of cleared supernatant as input. Subsequently, IP-protein beads were washed three times with PBS and 0.01% Tween-20, each for 5 min at 4°C. IP-proteins and their interacting partners were eluted from beads in 6X reducing loading buffer at 70°C for 15 min. Finally, samples were cooled down to room temperature and spun briefly to collect condensation. Standard Western blot procedures were applied using anti-Jarid2 (Novus Biologicals, NB100-2214) or anti-Ezh2 (Millipore, 17--662) antibodies. Blots were developed using HRP-conjugated anti-rabbit or -mouse antibodies, depending on the species of the primary antibody. Signals were developed and filmed by enhanced SuperSignal West Femto Maximum Sensitivity Substrate (Thermo, 34096). All exposures were done using hyper film.

Single molecular RNA FISH {#s4-10}
-------------------------

ESC\~MNs were cultured and harvested on slides. Cells were fixed in 4% paraformaldehyde for 10 min at room temperature, permeabilized for 5 min on ice in PBS with 0.5% Triton X-100, and then rinsed in 70% EtOH for subsequent RNA FISH. Slides and coverslips were kept in 70% EtOH at 4°C until staining. Slides were then washed in wash buffer (10% deionized formamide in 2X SSC) for 5 min and incubated in a dark room at 37°C for at least 4 hr with 1 μL of probe stock solution and 100 μL of hybridization buffer (1 g dextran sulfate, 1 mL 20X SSC, 1 mL deionized formamide). *Meg3* smFISH probes were purchased from Stellaris. Images were captured with a Delta Vision microscopy system.

RNA immunoprecipitation (RIP) {#s4-11}
-----------------------------

RIP was performed with the RNA-Binding Protein Immunoprecipitation Kit (17--700, Millipore) according to the manufacturer's protocol with some modifications. ESC\~MNs were dissociated at a concentration of 2 million cells/mL and treated with 0.3% formaldehyde in ice-cold PBS for 10 min at 37°C. Glycine/PBS was added to a final concentration of 0.125 M and each sample was incubated for 5 min at room temperature. After crosslinking, ten million cells were washed twice with cold PBS and then suspended in 100 μL RIP lysis buffer (with the addition of protease inhibitor and RNase inhibitor). The lysate was incubated on ice for 5 min and centrifuged at 14,000 rpm for 10 min at 4°C. Ezh2, Jarid2, and Suz12 antibodies were added for respective IP reactions and then incubated in RIP buffer (0.5 M EDTA/RNase inhibitor) for 3 hr to overnight at 4°C. Samples were washed at least five times with RIP washing buffer. RIP beads were resuspended in RIPA buffer (RIP washing buffer +10% SDS +protease K) to reverse crosslinking at 56°C for 30 min. RNA samples were extracted and qPCR was performed as described above. Isolated proteins before proteinase K treatment were collected from the beads and verified by Western blot analysis. Data on retrieved RNAs was calculated from the RT/input ratio for each experiment.

Statistical analyses and graphical representations {#s4-12}
--------------------------------------------------

All statistical analyses were generated with GraphPad Prism 6 (GraphPad Software). The values are shown as mean ± SD, as indicated. Student's *t*-tests were used for comparisons between experimental samples and controls. Statistical significance was defined as \* p\<0.05 and \*\* p\<0.01 by Student's *t*-test.

RNA-seq analysis {#s4-13}
----------------

Adapter contamination in the paired-end reads was removed using PEAT ([@bib46]), and the trimmed reads were aligned to the mm10 genome with STAR ([@bib26]). The standard GTF-formatted transcript annotation was defined by GENCODE (version M9) ([@bib32]), which includes many evidence-based lncRNAs. We used this annotation to aid the junction read alignment in STAR, the output of which was submitted to Cufflinks ([@bib91]) for de novo transcript assembly with the option 'library type; first-strand' to allow strand-specific alignments. We followed a strategy for novel lncRNA identification similar to that suggested by a previous report ([@bib75]), by which only transcripts that were longer than 200 bp, had no overlap with any known genes, and consisted of more than one exon were regarded as novel lncRNAs. We pooled these novel lncRNAs along with all known genes annotated in GENCODE and used HTseq ([@bib3]) to calculate the read count aligned onto each transcript. This procedure was repeated for all RNA-seq samples in this study. The read counts of all transcripts among different samples were normalized using a TMM algorithm with the trimming option M = 30% and A = 5% ([@bib80]). A general comparison of different normalization algorithms can be found in [@bib52]. We calculated the specificity score of each transcript among the samples at different stages according to the Jensen--Shannon definition for tissue specificity scores ([@bib6]; [@bib91]). The transcripts were split into three groups---namely protein coding genes, annotated lncRNAs, and novel lncRNAs---for which specificity score distributions were plotted and compared.

ChIP-seq analysis {#s4-14}
-----------------

Reads were trimmed by PEAT and aligned to the mm10 genome using Bowtie2 ([@bib43]). Following a similar flow analysis described in our previous work ([@bib10]; [@bib99]), all alignments were extended downstream to span an exact 150 bp-long region. Extensions that exceeded the ends of chromosomes were clipped. The extended alignments were input into the *genomecov* functionality supported in the BEDTools suite ([@bib76]) to generate read coverage profiles at a base-pair resolution. The coverage for each chromosomal position was normalized according to the mappable read count. Each sample was averaged and binned to reveal major trends. To identify possible differentially-enriched histone marks among stages or treatments, we used MACS 1.4 ([@bib28]) to call peaks (p-value\<10^−5^) in each ChIP-seq sample with the corresponding input library and then overlapping peaks were merged using MAnorm ([@bib83]) to reveal loci with a significant change between two samples.

Axon arborization quantification with Imaris {#s4-15}
--------------------------------------------

The 3D images acquired with a Zeiss Lightsheet Z.1 microscope were subjected to analyses in Imaris 8.4.0 (Bitplane, Zurich, Switzerland) for quantification of axon arborization. Regions of interest were segmented for detection of individual neurons. Motor nerve terminals were semi-automatically traced using the filament tracer wizard from a defined starting point. The AutoPath (no loops) algorithm was selected. Seed points detected from background signals were manually removed. Disconnected segments were removed by indicating the maximum gap length, and background subtraction was applied for noise removal. The 'Filament No. Dendrite Terminal Points' tool automatically calculated the number of motor nerve terminals.
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###### Cell type enriched lncRNAs from ESC to ESC**\~**MNs.

Values indicate the stage-specific scores (see Materials and methods), 70 stage-signature lncRNAs during the ESC\~MN differentiation process are uncovered (ESC, NE, pMN, MN, and IN showed in [Figure 1C](#fig1){ref-type="fig"}).

###### MN-enriched lncRNAs uncovered from RNA-seq.

Only the highly expressed (TMM normalized read count \>10 in all samples) lncRNAs are shown.

Data availability {#s7}
=================

All microarray, RNA-seq, ChIP-seq data have been deposited in GEO under accession codes GSE114283, GSE114285 and GSE114228.

The following datasets were generated:

Jun-AnChenYa-PingYen2018Genome-wide maps of H3K27me3 in chromatin state in embryonic stem cells differentiated motor neuronsNCBI Gene Expression OmnibusGSE114283

Jun-AnChenYa-PingYen2018Transcriptome analysis of Meg3 KD and IG-DMR maternal deletion in ESC, pMN, and MNNCBI Gene Expression OmnibusGSE114228

Jun-AnChenYa-PingYen2018Next Generation Sequencing Facilitates Quantitative Analysis of ES, pMN, MN, and IN TranscriptomesNCBI Gene Expression OmnibusGSE114285

The following previously published datasets were used:

MazzoniEOMahonySMorrisonCANedelecSGiffordDKWichterleH2013Induced V5-tagged Lhx3 (iLhx3-V5) in iNIL3-induced motor neurons (Day 4)NCBI Gene Expression OmnibusGSM782847

MazzoniEOMahonySMorrisonCANedelecSGiffordDKWichterleH2013Isl1/2 in iNIL3-induced motor neurons (Day 4)NCBI Gene Expression OmnibusGSM782848

NarendraVAnDMazzoniEReinbergD2015H3K4me3NCBI Gene Expression OmnibusGSM1468401

RheeHClosserMGuoYBashkirovaEVTanGCGiffordDKWichterleH2016H3K27ac_day6NCBI Gene Expression OmnibusGSM2098385

RheeHClosserMGuoYBashkirovaEVTanGCGiffordDKWichterleH2016ATAC_seq_day6NCBI Gene Expression OmnibusGSM2098391

MazzoniEOMahonySAMcCuineSYoungRAWichterleHGiffordDK2011RAR_Day2+8hrsRANCBI Gene Expression OmnibusGSM482750

MazzoniEOMahonySAMcCuineSYoungRAWichterleHGiffordDK2011Pol2-S5P_Day2+8hNCBI Gene Expression OmnibusGSM981593

ChenJYenY2017ES-WTNCBI Gene Expression OmnibusGSM2420680

ChenJYenY2017AK4-WTNCBI Gene Expression OmnibusGSM2420683

ChenJYenY2017AK7-WTNCBI Gene Expression OmnibusGSM2420684
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Decision letter

Sánchez Alvarado

Alejandro

Reviewing Editor

Stowers Institute for Medical Research

United States

In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.

Thank you for sending your article entitled \"*Dlk1-Dio3* Locus-Derived LncRNAs Perpetuate Postmitotic Motor Neuron Cell Fate and Subtype Identity\" for peer review at *eLife*. Your article is being evaluated by two peer reviewers, and the evaluation is being overseen by a Reviewing Editor and Marianne Bronner as the Senior Editor.

Summary:

The function of most lncRNAs in nervous system development remains largely unknown. This study by Yen et al. aims to address this knowledge gap by focusing on the imprinted *Dlk1-Dio3* locus, which produces three protein-coding genes (*Dlk1, Rtl1, Dio3*) from the paternally inherited allele and multiple lncRNAs (*Meg3, Rian, Mirg*) and small ncRNAs from the maternally inherited allele. Although this locus has been studied for years, the authors have discovered a new role for the *Dlk1-Dio3* locus-derived lncRNAs in post-mitotic motor neurons (MNs). The authors find that *Meg3* is induced in MN differentiation in response to retinoic acid and that *Meg3* affects PRC2-Jarid2 complex assembly. *Meg3* knockdown cause H3K27me3 depletion and gene induction at several 5\' *Hox* genes and the authors nicely show that this is associated with altered motor neuron identity and nerve targeting in vivo. Through a combination of elegant biochemical approaches in mESC-derived MNs, the authors find that these lncRNAs function through PRC2 (via gene repression) and have a dual role: (a) repression of progenitor/non-neural fate, and (b) establishment of MN subtype identity via repression of caudal *Hox* genes. This work represents a significant contribution as it aims to uncover the role of the lncRNAs of the mammalian imprinted *Dlk1-Dio3* locus in neuronal development. In addition, the authors devote significant effort into translating the in vitro mESC-derived MN findings to the mouse spinal cord. That being said, the authors should address the following concerns.

Essential revisions:

1\) A major conclusion of this paper is that *Dlk1-Dio3* locus-derived lncRNAs (*Meg3*) repress progenitor genes in MNs. However, it has not been demonstrated that *Dbx1* de-repression occurs in post-mitotic MNs of IG DMR mice. This point could be further consolidated by discovering additional progenitor genes that are de-repressed in vivo in IG DMR mice. The list generated via RNA-seq on mESC-derived MNs contains additional candidates (*Pax6, Neurog2*).

2\) By performing *Meg3* knock-down in mESC-derived MNs, the authors show effects on progenitor genes and *Hox* genes. However, it remains to be shown in vivo whether loss or knock-down of *Meg3* results in similar effects. They indirectly conclude that this is the case by using the IG DMR mice (although *Meg3* down-regulation in post-mitotic MNs of IG DMR mice is not shown), but in these mice concomitant up-regulation of paternal coding genes occurs (Lin et al., 2003, 2007), including *Dlk1* (known to affect MN development). In addition, the IG DMR mESC-MNs show massive differences in gene expression that are not found in *Meg3* KD ESC-MNs (Figure 4C). These differences could contribute to the phenotypes observed in IG DMR spinal cords. This concern could be addressed by a more targeted approach to knock-out or knock-down (shRNA) *Meg3* in the mouse spinal cord. Along the same lines, I do not understand the argument made in Discussion (subsection "Combinatorial and individual roles of the *Meg3-Rian-Mirg* lncRNA cluster") about not using the available mouse KO lines for *Meg3*. The *Meg3* KO mice represent a more elegant/targeted approach to perturb *Meg3* compared to IG DMR mice.

3\) Through elegant biochemistry, the authors show that *Meg3* interacts with PRC2 components and Jarid2. If this model is correct, we can make 2 predictions: (a) ChIP for PRC2 (Ezh2, Suz12) or Jarid2 and subsequent qPCR will reveal binding to progenitor genes and *Hox* genes. (b) And if *Meg3* is required for Ezh2/Jarid2 interaction, then PRC2/Jarid2 binding to DNA should be compromised in *Meg3* KD ESC-derived MNs. The authors have the necessary expertise for this experiment.

4\) Likewise, *Meg3* interaction with Ezh2 and Jarid2: The authors find that genetic manipulation of *Meg3*(V5) isoform affects the co-IP of Ezh2 and Jarid2, and conclude that *Meg3* facilitates Ezh2-Jarid2 complex assembly directly. This is a major claim of the paper that is not fully substantiated. What is the copy number of Ezh2, Jarid2, and *Meg3*? Is the copy number of *Meg3* sufficient to mediate this effect? Are there independent binding sites on *Meg3* for different subunits of the PRC2-Jarid complex, and how can the authors rule out indirect effects of *Meg3* on cell state that affects PRC2 complex assembly?

5\) The authors use biotinylated *Meg3* RNA to retrieve Ezh2 from MN cell extract, and then conclude this demonstrates \"direct interaction\" between *Meg3* and Ezh2 (subsection "*Meg3* facilitates interaction of the PRC2 complex with Jarid2 in MNs", first paragraph). This is incorrect as the extract contains a multitude of proteins. UV crosslinking in cells or in vitro reconstitution with purified components is needed to make such a conclusion.

6\) The presence of multiple long and small regulatory RNAs from the *Dlk1-Dio3* locus somewhat complicates the interpretation of these results. The use of *Meg3*(v5) transgene to rescue is informative, but this was only done for a subset of experiments. The authors should take this into account more in the Discussion.

Major concerns that do not require experiments:

1\) Why were the experiments shown in Figure 3C-G done on ESC and not ESC-derived MNs? At minimal, an explanation must be provided. This is important because at the end of the subsection "*Meg*3 facilitates interaction of the PRC2 complex with Jarid2 in MNs", the authors conclude that *Meg3* facilitates binding of PRC2 and Jarid2 in post-mitotic MNs. Also, this argument could be strengthened by providing evidence that Jarid2 is expressed in vivo in spinal MNs. Similarly, it appears that *Meg3* knock-down was performed at the ESC stage, not at the progenitor MN or post-mitotic MN stage? The reason for this should be clearly stated in Results because this point is raised in Discussion (subsection "PRC1/2 with lncRNA: a fail-safe mechanism to guard MN epigenetic landscape", last paragraph) but with little justification.

2\) The authors compare data from other studies performed in ESC-derived MNs. However, it is not clearly stated whether all these studies generate the same \"type\" of MNs. Do all these previous studies generate mESC-derived MNs of \"rostral\" identity? If yes, this should be added in the text because: (i) it makes sense then that by profiling these MNs the authors found *Meg3*, which is highly expressed in rostral spinal cord, (ii) it will also help the reader in Discussion (subsection "PRC2-lncRNA regulation in MNs", first paragraph) when the authors talk about cervical MNs.

3\) In Discussion, similarities and differences between the mechanism described by the authors and previous studies on the lncRNA *HOTAIR* (also works with PRC2 to repress caudal *Hox*) could be discussed (PMID: 17604720, PMID: 20616235).

4\) The authors find that *Meg3* is enriched in rostral MNs. However, in Figure 4---figure supplement 1E, *Meg-3* knock-down results in loss of rostral *Hox* gene expression and gain of caudal *Hox* gene expression. The authors should at least discuss how Polycom-mediated gene repression results in these 2 different effects on *Hox* gene expression, especially in light of the fact that these results are not phenocopied in vivo with the IG-DMR mice.

Reviewer \#1:

Yen et al. present an integrated analysis of the *Meg3* imprinted lncRNA in motor neuron differentiation. The authors find that *Meg3* is induced in MN differentiation in response to retinoic acid, and that *Meg3* affects PRC2-Jarid2 complex assembly. *Meg3* knock down cause H3K27me3 depletion and gene induction at several 5\' *Hox* genes, and the authors nicely show that this is associated with altered motor neuron identity and nerve targeting in vivo. The strength of this work is the use of rigorous genetic models to validate the model that lncRNA regulates *Hox* loci in trans and thereby alter neuronal cell positional identity. The mechanistic details are not yet fully clear, which the authors should be more cautious in their interpretations.

1\) *Meg3* interaction with Ezh2 and Jarid2: The authors find that genetic manipulation of *Meg3*(V5) isoform affects the co-IP of Ezh2 and Jarid2, and conclude that *Meg3* facilitates Ezh2-Jarid2 complex assembly directly. This is a major claim of the paper that is not fully substantiated. What is the copy number of Ezh2, Jarid2, and *Meg3*? Is the copy number of *Meg3* sufficient to mediate this effect? Are there independent binding sites on Meg3 for different subunits of the PRC2-Jarid complex, and how can the authors rule out indirect effects of *Meg3* on cell state that affects PRC2 complex assembly?

2\) The authors use biotinylated *Meg3* RNA to retrieve Ezh2 from MN cell extract, and then conclude this demonstrates \"direct interaction\" between *Meg3* and Ezh2 (subsection "*Meg3* facilitates interaction of the PRC2 complex with Jarid2 in MNs", first paragraph). This is incorrect as the extract contains a multitude of proteins. UV crosslinking in cells or in vitro reconstitution with purified components is needed to make such a conclusion.

3\) The presence of multiple long and small regulatory RNAs from the *Dlk1-Dio3* locus somewhat complicates the interpretation of these results. The use of *Meg3*(v5) transgene to rescue is informative, but this was only done for a subset of experiments. The authors should take this into account more in the Discussion.

Reviewer \#2:

The function of most lncRNAs in nervous system development remains largely unknown. This study by Yen et al. aims to address this knowledge gap by focusing on the imprinted *Dlk1-Dio3* locus, which produces three protein coding genes (*Dlk1, Rtl1, Dio3*) from the paternally inherited allele and multiple lncRNAs (*Meg3, Rian, Mirg*) and small ncRNAs from the maternally inherited allele. Although this locus has been studied for years, the authors have discovered a new role for the *Dlk1-Dio3* locus-derived lncRNAs in post-mitotic motor neurons (MNs). By using a well-established in vitro differentiation protocol to generate MNs from stem cells, the authors first provide a mini-resource (although the majority of genes were not validated) of lncRNAs that show cell-type specificity during different stages of MN development (NE, pMN, MN). This resource revealed that the *Dlk1-Dio3* locus-derived lncRNAs (*Meg3, Rian, Mirg*) are enriched in post-mitotic MNs in vitro, and further demonstrated that *Meg3* is expressed in developing mouse spinal MNs in vivo (high rostral/low caudal). Through a combination of elegant biochemical approaches in mESC-derived MNs, the authors find that these lncRNAs function through PRC2 (via gene repression) and have a dual role: (a) repression of progenitor/non-neural fate, and (b) establishment of MN subtype identity via repression of caudal *Hox* genes.

This work represents a significant contribution as it aims to uncover the role of the lncRNAs of the mammalian imprinted *Dlk1-Dio3* locus in neuronal development. In addition, the authors devote significant effort into translating their in vitro mESC-derived MN findings to the mouse spinal cord. However, I do have several major concerns that moderated enthusiasm.

Major concerns that require experiments:

1\) A major conclusion of this paper is that *Dlk1-Dio3* locus-derived lncRNAs (*Meg3*) repress progenitor genes in MNs. However, it has not been demonstrated that *Dbx1* de-repression occurs in post-mitotic MNs of IG DMR mice. This point could be further consolidated by discovering additional progenitor genes that are de-repressed in vivo in IG DMR mice. The list generated via RNA-seq on mESC-derived MNs contains additional candidates (*Pax6, Neurog2*).

2\) By performing *Meg3* knock-down in mESC-derived MNs, the authors show effects on progenitor genes and *Hox* genes. However, it remains to be shown in vivo whether loss or knock-down of *Meg3* results in similar effects. They indirectly conclude that this is the case by using the IG DMR mice (although *Meg3* down-regulation in post-mitotic MNs of IG DMR mice is not shown), but in these mice concomitant up-regulation of paternal coding genes occurs (Lin et al., 2003, 2007), including *Dlk1* (known to affect MN development). In addition, the IG DMR mESC-MNs show massive differences in gene expression that are not found in *Meg3* KD ESC-MNs (Figure 4C). These differences could contribute to the phenotypes observed in IG DMR spinal cords. This concern could be addressed by a more targeted approach to knock-out or knock-down (shRNA) *Meg3* in the mouse spinal cord. Along the same lines, I do not understand the argument made in Discussion (subsection "Combinatorial and individual roles of the *Meg3-Rian-Mirg* lncRNA cluster") about not using the available mouse KO lines for *Meg3*. The *Meg3* KO mice represent a more elegant/targeted approach to perturb Meg3 compared to IG DMR mice.

3\) Through elegant biochemistry, the authors show that *Meg3* interacts with PRC2 components and Jarid2. If this model is correct, we can make 2 predictions: (a) ChIP for PRC2 (Ezh2, Suz12) or Jarid2 and subsequent qPCR will reveal binding to progenitor genes and *Hox* genes. (b) And if *Meg3* is required for Ezh2/Jarid2 interaction, then PRC2/Jarid2 binding to DNA should be compromised in *Meg3* KD ESC-derived MNs. The authors have the necessary expertise for this experiment.

Major concerns that do not require experiments:

1). Why the experiments shown in Figure 3C-G were done on ESC and not ESC-derived MNs? At minimal, an explanation must be provided. This is important because at the end of the subsection "*Meg3* facilitates interaction of the PRC2 complex with Jarid2 in MNs", the authors conclude that *Meg3* facilitates binding of PRC2 and Jarid2 in post-mitotic MNs. Also, this argument could be strengthened by providing evidence that Jarid2 is expressed in vivo in spinal MNs. Similarly, it appears that *Meg3* knock-down was performed at the ESC stage, not at the progenitor MN or post-mitotic MN stage? The reason for this should be clearly stated in Results because this point is raised in Discussion (subsection "PRC1/2 with lncRNA: a fail-safe mechanism to guard MN epigenetic landscape", last paragraph) but with little justification.

2\) The authors compare data from other studies performed in ESC-derived MNs. However, it is not clearly stated whether all these studies generate the same \"type\" of MNs. Do all these previous studies generate mESC-derived MNs of \"rostral\" identity? If yes, this should be added in the text because: (i) it makes sense then that by profiling these MNs the authors found *Meg3*, which is highly expressed in rostral spinal cord, (ii) it will also help the reader in Discussion (subsection "PRC2-lncRNA regulation in MNs", first paragraph) when the authors talk about cervical MNs.

3\) In Discussion, similarities and differences between the mechanism described by the authors and previous studies on the lncRNA *HOTAIR* (also works with PRC2 to repress caudal *Hox*) could be discussed (PMID: 17604720, PMID: 20616235).

4\) The authors find that *Meg3* is enriched in rostral MNs. However, in Figure 4---figure supplement 1E, *Meg-3* knock-down results in loss of rostral *Hox* gene expression and gain of caudal *Hox* gene expression. The authors should at least discuss how Polycom-mediated gene repression results in these 2 different effects on *Hox* gene expression, especially in light of the fact that these results are not phenocopied in vivo with the IG-DMR mice.

10.7554/eLife.38080.sa2

Author response

> Essential revisions:
>
> 1\) A major conclusion of this paper is that Dlk1-Dio3 locus-derived lncRNAs (Meg3) repress progenitor genes in MNs. However, it has not been demonstrated that Dbx1 de-repression occurs in post-mitotic MNs of IG DMR mice. This point could be further consolidated by discovering additional progenitor genes that are de-repressed in vivo in IG DMR mice. The list generated via RNA-seq on mESC-derived MNs contains additional candidates (Pax6, Neurog2).

We thank the reviewer for this suggestion to strengthen our conclusion that progenitor genes are derepressed in the *IG-DMR^matΔ^* embryos. In revised new Figure 5---figure supplement 1A, we first verified that the expression of *Meg3* is still lacking in the developing spinal cord of E14.5 *IGDMR^matΔ^* embryos. We then checked the progenitor proteins Pax6, Irx3and Dbx1 (data not shown for Dbx1 as Dbx1 antibody did not work well for immunostaining). Compared to the control littermates, we observed a significant increase in the percentage of Pax6^on^ (45% penetrance, n = 5/11), and Irx3^on^ cells (100% penetrance, n = 8/8) for postmitotic MNs (Isl1/2^on^) along the entire rostrocaudal axis of the dorsal spinal cord in the *IG-DMR^matΔ^* embryos (new Figures 5A and 5C, only the cervical segment is shown; quantifications shown in new Figures 5B and 5D). However, Hb9^on^ and Isl1(2)^on^ MNs were comparable between the control and *IG-DMR^matΔ^* embryos at E10.5 (new Figures 5E and 5F). Although dorsal progenitor genes were aberrantly up-regulated in the postmitotic MNs, production of MNs remained relatively unaffected, suggesting that the generation of MNs is still intact with the co-expressed progenitor/postmitotic genes in the *IG-DMR^matΔ^* embryos (new Figure 5G). This outcome is consistent with the postmitotic expression of *Meg3* and its function to maintain the silenced epigenetic state of progenitor genes.

Although we observed a complete 100% penetrance of Hoxa5-c8 cell fate switch in the rostrobrachial segments and an increase co-expression of Irx3^on^Hb9^on^ cells in the *IG-DMR^matΔ^* embryos (Figures 5 and 6), ectopic Pax6 was manifested at partial penetrance (45% , 5 in the 11 mutants) and several caudal Hox protein (including Hox9 and 10) were not shown to display significant changein vivo (Figures 5 and Figure 5---figure supplement 1), consistent with the finding that removal of *Ezh2* from MN progenitors has no detectable impact on segmental Hox expression in the spinal cord (Hoxc6 and Hoxc9) (Golden and Dasen, 2012). This result also suggests that a compensatory PRC1-mediated function in vivo might make up for the loss of *Meg3*-mediated epigenetic maintenance in segmental MNs (Golden and Dasen, 2012; Mazzoni et al., 2013). Our results are not entirely unexpected as many potent miRNA/lncRNA KO mice reflect either only partial phenotype penetrance (Li et al., 2013; Li et al., 2016; Medeiros et al., 2011), or more severe phenotypes upon genetic or environmental stresses (Williams et al., 2009). Moreover, many miRNAs/TFs function as repressors to silence progenitor/neighboring interneuron genes (Chen et al., 2011; Shirasaki and Pfaff, 2002), they may also constitute a coherent loop with lncRNAs to safeguard the terminal postmitotic cell fate with a fail-safe control. This part is now added in the Discussion subsection "A fail-safe mechanism to guard MN epigenetic landscape", last paragraph.

> 2\) By performing Meg3 knock-down in mESC-derived MNs, the authors show effects on progenitor genes and Hox genes. However, it remains to be shown in vivo whether loss or knock-down of Meg3 results in similar effects. They indirectly conclude that this is the case by using the IG DMR mice (although Meg3 down-regulation in post-mitotic MNs of IG DMR mice is not shown), but in these mice concomitant up-regulation of paternal coding genes occurs (Lin et al., 2003, 2007), including Dlk1 (known to affect MN development). In addition, the IG DMR mESC-MNs show massive differences in gene expression that are not found in Meg3 KD ESC-MNs (Figure 4C). These differences could contribute to the phenotypes observed in IG DMR spinal cords. This concern could be addressed by a more targeted approach to knock-out or knock-down (shRNA) Meg3 in the mouse spinal cord. Along the same lines, I do not understand the argument made in Discussion (subsection "Combinatorial and individual roles of the Meg3-Rian-Mirg lncRNA cluster") about not using the available mouse KO lines for Meg3. The Meg3 KO mice represent a more elegant/targeted approach to perturb Meg3 compared to IG DMR mice.

We appreciate the reviewer's comment and apologize for not more clearly explaining our rationale. We did not use *Meg3* KO as both *Meg3* KO mice lines manifested loss of maternal *Rian* and *Mirg* lncRNA expression.In particular, the Japanese *Meg3* KO mice in which \~10 kb is deleted, including the *Meg3*-DMR region and the first five exons of *Meg3* (Takahashi et al., 2009), also causes aberrant expression of paternal genes. This outcome is consistent with our results that most, if not all, lncRNAs in the *Meg3-Rian-Mirg* locus are reduced upon *Meg3* KD and in IG-*DMR^MatΔ^*. Therefore, it remains technically challenging to obtain a specific *Meg3* KO without abrogating the expression levels of downstream lncRNAs. We hope the reviewer can appreciate that it is a longstanding challenge in the field to dissect the role of maternal lncRNAs in the regulation of *Dlk1Dio3* locus imprinting control (McMurray and Schmidt, 2012; Steshina et al., 2006; Takahashi et al., 2009; Zhou et al., 2010), and that several labs have attempted to tackle the topic but failed to generate a clear answer. We now explain our rationale more clearly in the revised Discussion (subsection "Combinatorial and individual roles of the *Meg3-Rian-Mirg* lncRNA cluster").

As our current and previous results indicated that the expressions of most lncRNAs in the *Meg3-Rian-Mirg* locus are reduced upon *Meg3* KD and in *IG-DMR^MatΔ^* (Figure 4---figure supplement 1A)(Lin et al., 2003), it remains puzzling if these ncRNAs work independently or synergistically in this locus to regulate MNs. To further parse this question, we generated two single lncRNA *Rian^Δ/Δ^*and *Mirg^Δ/Δ^* ESCs respectively by using CRISPR-Cas9 mediated approaches (new Figure 8A). The design of the targeted deletion regions of *Rian* and *Mirg* followed two previous studies (Han et al., 2014; Labialle et al., 2014), which led to a 23 kb deletion in the *Rian^Δ/Δ^* ESC and a 20 kb deletion in the *Mirg^Δ/Δ^* ESC (new Figure 8A). We first verified that the paternal gene (i.e., *Dlk1*) is not affected in either *Rian^Δ/Δ^*or *Mirg^Δ/Δ^* ESCs. In the *Rian^Δ/Δ^*ESCs, expressions of *Meg3* and *Mirg* were relatively unaffected, whereas that of *Rian* was compromised. Conversely, only expression of *Mirg* was impaired significantly in the *Mirg^Δ/Δ^* ESCs, but expressions of *Meg3* and *Rian* manifested minimal changes in that cell line (new Figure 8B). Upon differentiation, *Meg3* KD MNs showed ectopic up-regulated expressions of progenitor and caudal *Hox* genes (Figure 4 and new Figure 8C). In contrast, expression of *Hoxa5* remained unchanged in the *Rian^Δ/Δ^*and *Mirg^Δ/Δ^* MNs, while *Pax6* and *Hoxc8* expressions were restored to similar levels to control ESC\~MNs (new Figure 8C). These results indicate that *Meg3* might be the major regulatory lncRNA responsible for the observed MN phenotype displayed by the *IG-DMR^matΔ^* embryos (new Figure 8D).

Although our new results indicate that *Meg3* might be the major regulatory lncRNA and largely accounts for the observed MN phenotype observed in the *IG-DMR^matΔ^* embryos, we cannot fully exclude the possibility of synergistic effects of the *Meg3-Rian-Mirg* locus. We discuss this possibility with new paragraphs in our Discussion section as follows:

"Combinatorial and individual roles of the *Meg3-Rian-Mirg* lncRNA cluster

There have been multiple efforts to dissect the functions of the maternally-expressed lncRNAs in the *Meg3-Rian-Mirg* locus over the past decade (McMurray and Schmidt, 2012; Steshina et al., 2006; Takahashi et al., 2009; Zhou et al., 2010), but definitive results remain elusive. \[...\] We anticipate that a detailed map of individual and synergetic lncRNA/miRNA functions during neural development attributable to this imprinted locus will be uncovered in the near future."

> 3\) Through elegant biochemistry, the authors show that Meg3 interacts with PRC2 components and Jarid2. If this model is correct, we can make 2 predictions: (a) ChIP for PRC2 (Ezh2, Suz12) or Jarid2 and subsequent qPCR will reveal binding to progenitor genes and Hox genes. (b) And if Meg3 is required for Ezh2/Jarid2 interaction, then PRC2/Jarid2 binding to DNA should be compromised in Meg3 KD ESC-derived MNs. The authors have the necessary expertise for this experiment.

As previous studies have elegantly performed Ezh2/Suz12 ChIP-seq in ESC\~MNs (using the same approach applied in this study), we have checked these available ChIP-seq data (Mazzoni et al., 2013; Narendra et al., 2015) and revealed that Ezh2 enrichment peaks are concordant with our H3K27me3 binding sites in the progenitor (i.e., *Pax6, Irx3, Dbx1*, and *Neurog2*) and caudal *Hox* genes. This information has been added into new Figure 4---figure supplement 2A, B.

We also verified that upon *Meg3* KD, binding of Ezh2/Jaird2 to progenitor (i.e., *Pax6*) and caudal *Hox* (i.e., *Hoxc8*) genes is concomitantly reduced (new Figure 4---figure supplement 2C-E).

> 4\) Likewise, Meg3 interaction with Ezh2 and Jarid2: The authors find that genetic manipulation of Meg3(V5) isoform affects the co-IP of Ezh2 and Jarid2, and conclude that Meg3 facilitates Ezh2-Jarid2 complex assembly directly. This is a major claim of the paper that is not fully substantiated. What is the copy number of Ezh2, Jarid2, and Meg3? Is the copy number of Meg3 sufficient to mediate this effect? Are there independent binding sites on Meg3 for different subunits of the PRC2-Jarid complex, and how can the authors rule out indirect effects of Meg3 on cell state that affects PRC2 complex assembly?
>
> 5\) The authors use biotinylated Meg3 RNA to retrieve Ezh2 from MN cell extract, and then conclude this demonstrates \"direct interaction\" between Meg3 and Ezh2 (subsection "Meg3 facilitates interaction of the PRC2 complex with Jarid2 in MNs", first paragraph). This is incorrect as the extract contains a multitude of proteins. UV crosslinking in cells or in vitro reconstitution with purified components is needed to make such a conclusion.

Points \#4 and 5 raise three related issues:

a\) Is the interaction between *Meg3* and Ezh2/Jarid2 direct?

b\) Does *Meg3* bind to other proteins in the PRC2 complex via indirect interactions?

c\) Is *Meg3* copy number sufficient to mediate the pervasive PRC2/Jarid2 complex?

To address these issues, we reshaped our conclusions and performed additional experiments as follows:

1\) Dr. Danny Reinberg's laboratory has shown that JARID2/EZH2 retrieved *MEG3* via PAR-CLIP, a strong indication of direct interaction (Kaneko et al., 2014a). We discuss this study more clearly in our revised manuscript (subsection "Regulatory mode of *Meg3* for the PRC2/Jarid2 complex").

2\) Previously, we performed both qPCR and single molecule FISH on *Meg3* and revealed its abundance in postmitotic MNs (Figure 2---figure supplement 1A, D). The PRC2 complex methylates histones for epigenetic silencing and associates with thousands of protein-coding and noncoding RNAs. The impact of RNA binding on PRC2 recruitment and activity were elegantly shown by previous studies (Cifuentes-Rojas et al., 2014; Davidovich et al., 2013). Based on our analysis of the RNA-seq data generated from our ESC\~MN approach, we have added an analysis to our revised manuscript to show that the copy number of *Meg3/Rian* is much more abundant than that for many other *cis*- and *trans*-acting lncRNAs known to bind the PRC2 complex, including *Xist, Kcnqtlot1*, and *Hotair* (new Figure 3---figure supplement 1A).

3\) We also understand that even with the above-described results, it is not possible to completely rule out that *Meg3* binds to other PRC2 proteins indirectly to contribute to PRC2/Jarid2 recruitment, activity control, and targeting mode. This topic represents a big challenge in the lncRNA/epigenetics field. Our aim in this study is to illustrate the importance and unexpected functions of lncRNAs in the well-known imprinted *Dlk1-Dio3* locus during neural development. We now highlight in our revised manuscript that future experiments, including *Meg3* ChIRP-seq/MS and Ezh2/Jarid2 CLIP-seq, will help reveal the comprehensive interaction and targeting mode of the *Meg3*/PRC2/Jarid2 interactome. Our revised discussion of this topic is as follows:

"Regulatory mode of *Meg3* for the PRC2/Jarid2 complex

The role of lncRNAs in modulating PRC2 function is well documented, but very dynamic; from recruitment, complex loading and activity control to gene targeting (Davidovich and Cech, 2015; Kretz and Meister, 2014). \[...\] Future systematic *Meg3* ChIRP-seq analyses, together with Ezh2/Jarid2 CLIP-seq, at all stages of ESC\~MN differentiation might aid in identifying the context-dependent/independent lncRNA-mediated PRC2 targeting strategy."

> 6\) The presence of multiple long and small regulatory RNAs from the Dlk1-Dio3 locus somewhat complicates the interpretation of these results. The use of Meg3(v5) transgene to rescue is informative, but this was only done for a subset of experiments. The authors should take this into account more in the Discussion.

In fact, unraveling the essential role of *Meg3* in the region of *Meg3-Rian-Mirg* is a longstanding question. Given that *Meg3* is more than 15 kb and has more than 10 variants, it is very challenging to address this issue. Although it is not a perfect approach, we instead generated two single lncRNA *Rian^Δ/Δ^*and *Mirg^Δ/Δ^*knockout ESC lines using CRISPR-Cas9-mediated approaches to address this issue (new Figure 8). Details are specified in point \#2 above.

> Major concerns that do not require experiments:
>
> 1\) Why were the experiments shown in Figure 3C-G done on ESC and not ESC-derived MNs? At minimal, an explanation must be provided. This is important because at the end of the subsection "Meg3 facilitates interaction of the PRC2 complex with Jarid2 in MNs", the authors conclude that Meg3 facilitates binding of PRC2 and Jarid2 in post-mitotic MNs. Also, this argument could be strengthened by providing evidence that Jarid2 is expressed in vivo in spinal MNs. Similarly, it appears that Meg3 knock-down was performed at the ESC stage, not at the progenitor MN or post-mitotic MN stage? The reason for this should be clearly stated in Results because this point is raised in Discussion (subsection "PRC1/2 with lncRNA: a fail-safe mechanism to guard MN epigenetic landscape", last paragraph) but with little justification.

We apologize for the confusion and typo. All of the experiments in Figure 3 were performed on ESC\~MNs, rather than ESCs. We have corrected this error in the revised manuscript.

We did not knockdown *Meg3* in postmitoic MNs simply due to the technical difficulty of performing lentivirus-mediated knockdown in embryoid bodies (EBs), which are notoriously challenging to infect given their 3D spherical shape. We have therefore added the following sentence to our revised Discussion:

"Given that *Meg3* is also highly expressed in ESCs (Kaneko et al., 2014a; Mo et al., 2015), we plan to generate a targeted *Meg3* floxed allele mouse line in the future that will allow us to specifically knockout *Meg3* in MNs and recover the potential function of *Meg3* in cell-type specific contexts."

> 2\) The authors compare data from other studies performed in ESC-derived MNs. However, it is not clearly stated whether all these studies generate the same \"type\" of MNs. Do all these previous studies generate mESC-derived MNs of \"rostral\" identity? If yes, this should be added in the text because: (i) it makes sense then that by profiling these MNs the authors found Meg3, which is highly expressed in rostral spinal cord, (ii) it will also help the reader in Discussion (subsection "PRC2-lncRNA regulation in MNs", first paragraph) when the authors talk about cervical MNs.

We appreciate the reviewer's comments. We now specifically define our ESC\~MNs as being cervical Hoxa5^on^ in the revised manuscript as follows:

"Consistent with our prediction, we verified that 1) the epigenetic landscapes of H3K27me3 in the progenitor and caudal *Hox* genes uncovered here are concordant with Ezh2 enrichment revealed by a previous study that used the same ESC\~MN differentiation approach to generate cervical Hoxa5^on^ MNs (Figure 4---figure supplement 2A,B) (Narendra et al., 2015)."

"Together, these results strongly endorse the critical function of PRC2/lncRNA in perpetuating the postmitotic cell fate of cervical Hoxa5^on^ MNs."

> 3\) In Discussion, similarities and differences between the mechanism described by the authors and previous studies on the lncRNA HOTAIR (also works with PRC2 to repress caudal Hox) could be discussed (PMID: 17604720, PMID: 20616235).

We thank the reviewers for reminding us of these two landmark studies. Although these two papers were discussed and cited in our original submission, we now re-emphasize them in our revised manuscript as they inspired our study.

New revised Discussion:

"Given that lncRNAs such as *Hotair* are proposed to scaffold the PRC2 complex and guide it to specific genome loci (Rinn et al., 2007; Rinn and Chang, 2012; Tsai et al., 2010), it is tantalizing to hypothesize that *Meg3* might manifest the dual functions of scaffolding the PRC2/Jarid2 complex and guiding it to specific loci in different cell contexts. \[...\] Generating compound lncRNA mutants that can scaffold the PRC2/Jarid2 complex will shed light on this topic."

> 4\) The authors find that Meg3 is enriched in rostral MNs. However, in Figure 4---figure supplement 1E, Meg-3 knock-down results in loss of rostral Hox gene expression and gain of caudal Hox gene expression. The authors should at least discuss how Polycom-mediated gene repression results in these 2 different effects on Hox gene expression, especially in light of the fact that these results are not phenocopied in vivo with the IG-DMR mice.

It is an interesting point. ESC\~MNs exposed to RA activate the rostral portion of the *Hox* cluster (*Hox1*\~5), while *Hox6\~13* remain repressed. The transcriptional partitioning of the *Hox* cluster is mirrored at the level of chromatin. As previously described (Mazzoni et al., 2013), and also shown in this study, H3K27me3 decorates the entire *Hox* cluster in ESCs. Upon differentiation into MNs, H3K27me3 becomes restricted to the caudal segment (Narendra et al., 2015). It is still not clear how the "repressive epigenetic state of caudal Hox" is maintained in the rostral (cervical) MNs, as the PRC2 complex does not manifest a differential expression pattern along the RC axis of the spinal cord. In this study, we found that *Meg3* is enriched in the rostral (cervical) MNs, and is able to scaffold the PRC2/Jarid2 complex for the robust catalytic activity of depositing H3K27me3. We speculate that *Meg3* might be able to further help PRC2/Jarid2 to target to the caudal *Hox* loci to maintain its repressive H3K27me3 state. Upon *Meg3* KD in the cervical MNs, the silent H3K27me3 in caudal *Hox* loci is compromised. Therefore, the caudal *Hox* genes (i.e., *Hox8\~13*) become ectopically up-regulated. The rostral genes are likely repressed by the well-known "posterior prevalence" effect, while the ectopically up-regulated caudal Hox proteins silence the rostral *Hox* genes directly.
